Document:

EX-4.11

 Exhibit 4.11 

SUPERCONDUCTOR TECHNOLOGIES INC. 
 Warrant
Shares:
                                         
                                         
              Initial Exercise Date:                     , 2015 

THIS SERIES [A][B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received,
            or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
after             , 2015 (the “Initial Exercise Date”) and on or prior to the close of business on             ,
202[    ]1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Superconductor Technologies Inc., a Delaware corporation (the
“Company”), up to             shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common
Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). 
 Section 1.
Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”), dated
            , 2015, among the Company and the purchasers signatory thereto. 

Section 2. Exercise. 

(a) Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or
after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing
on the books of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise Form annexed hereto. Within three (3) Trading Days following the date of exercise as aforesaid, the Holder shall deliver the
aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in
the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to
the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder
shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total
number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount 
  

 

	1 	 6 months from Initial Exercise Date for Series A; 5 years from Initial Exercise Date for Series B.

  
 1 

 
equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The
Company shall deliver any objection to any Notice of Exercise Form within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of
this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof. 

(b) Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be
$            , subject to adjustment hereunder (the “Exercise Price”). 

(c) Cashless Exercise. If, and only if, at the time of exercise hereof there is no effective registration statement
registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the
Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where: 
  

	 	(A)	= the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless exercise,” as set forth in the applicable Notice of Exercise;

  

	 	(B)	= the Exercise Price of this Warrant, as adjusted hereunder; and 

  

	 	(X)	= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

 “VWAP” means, for any date, the price determined by the first of the following clauses that
applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then
listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTC Bulletin Board or OTCQB is not a Trading Market, the volume weighted average price of
the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board or OTCQB, as applicable, (c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board or OTCQB and if prices for the Common
Stock are then reported in the “Pink Sheets” published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or
(d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to
the Company, the fees and expenses of which shall be paid by the Company. 

  
 2 

 (d) Mechanics of Exercise. 

 

	 	i.	Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its
designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration
statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the
Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
three (3) Trading Days after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). The Warrant Shares shall be deemed to have been issued, and Holder or any other person so
designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if
permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having been paid. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to
a Notice of Exercise by the Warrant Share Delivery Date (provided that the Company has received the payment, unless by cashless exercise, with respect to such Exercise Notice on or before such date), the Company shall pay to the Holder, in cash, as
liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on
the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. 

ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at
the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by
this Warrant, which new Warrant shall in all other respects be identical with this Warrant. 
 iii. Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise. 

  
 3 

 iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon
Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after
such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant
Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the
exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery
obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such
purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in
respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. 

v. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the
exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount
equal to such fraction multiplied by the Exercise Price or round up to the next whole share. 

  
 4 

 vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made
without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the
name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall
pay all Transfer Agent fees required for same-day processing of any Notice of Exercise. 
 vii. Closing of Books. The
Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof. 

(e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall
not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with
the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is
being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise
or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation
contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of
the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the
Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the

  
 5 

 
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon
exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the
61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give
effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. 

Section 3. Certain Adjustments. 

(a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common
Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into
a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or
re-classification. 

  
 6 

 (b) [Reserved]. 

(c) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the
Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the
Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate
in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock
as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation). 
 (d) Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall
declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or
other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is
taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the Holder’s right to participate in any such
Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result
of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised
this Warrant. 

  
 7 

 (e) Fundamental Transaction. If, at any time while this Warrant is
outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease,
license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the
Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock
is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not
including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a
“Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company,
if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable by holders of Common Stock as a result of such Fundamental Transaction for each share of Common Stock for which this
Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a
Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a
Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the
provisions of this Section 

  
 8 

 
3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and
shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a
corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of
this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such
Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of
such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after
the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and
shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. 

(f) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of
a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if
any) issued and outstanding. 
 (g) Notice to Holder. 

i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this
Section 3, the Company shall promptly mail to the Holder a notice or file with the Commission a Current Report on Form 8-K setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and
setting forth a brief statement of the facts requiring such adjustment. 
 ii. Notice to Allow Exercise by Holder. If
(A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company
shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in
connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a 

  
 9 

 
party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or
property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed a notice to the Holder at its last address
as it shall appear upon the Warrant Register of the Company or file with the Commission a Current Report on Form 8-K, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, stating (x) the date on
which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share
exchange; provided that the failure to provide such notice or any defect therein shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or
contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise
this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. 

Section 4. Transfer of Warrant. 

(a) Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are
transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the
Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name
of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued. 

  
 10 

 (b) New Warrants. This Warrant may be divided or combined with other
Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to
compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. 

(c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. 
 Section 5.
Miscellaneous. 
 (a) No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any
voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. 

(b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of
evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory
to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of
like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. 
 (c) Saturdays, Sundays,
Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day. 
 (d) Authorized Shares. 

The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority
to 

  
 11 

 
its officers who are charged with the duty of executing stock certificates to execute and issue the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The
Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the
Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for
such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue). 
 Except and to the extent as waived or consented to by the Holder,
the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon
the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to
perform its obligations under this Warrant. 
 Before taking any action which would result in an adjustment in the number of
Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof. 
 (e) Jurisdiction. All questions concerning the construction, validity, enforcement and
interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement. 
 (f)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without
limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any 

  
 12 

 
material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’
fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. 

(g) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice procedures of the Purchase Agreement to such address provided by a Holder to the Company including if such Holder is not a party to the Purchase Agreement. 

(h) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise
this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such
liability is asserted by the Company or by creditors of the Company. 
 (i) Remedies. The Holder, in addition to being
entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. 

(j) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from
time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. 
 (k) Amendment. The
provisions of this Warrant and all of the other Warrants issued under the Purchase Agreement and otherwise issued to investors not party to the Purchase Agreement on the same original issuance date as this Warrant in the forms of the Series A
Warrants and Series B Warrants may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Persons holding
Warrants representing not less than a majority of the Common Stock obtainable upon exercise of all such Warrants then outstanding treating the Series A Warrants and Series B Warrants as a single class; provided, that the number of Warrant Shares
subject to this Warrant, the Exercise Price, the Initial Exercise Date and the Termination Date may not be amended, and the right to exercise this Warrant may not be altered or waived, without the written consent of the Holder. Any such amendment
shall apply to all Warrants and be binding upon all registered holders of such Warrants whether or not they have consented (except only for those amendments that, pursuant the preceding sentence, require the written consent of the Holder). 

  
 13 

 (l) Severability. Wherever possible, each provision of this Warrant shall
be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or
invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. 
 (m)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. 

******************** 

(Signature Page Follows) 

  
 14 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto
duly authorized as of the date first above indicated. 
  

			
	SUPERCONDUCTOR TECHNOLOGIES INC.
		
	By:	 	  

		 	 Name:
 Title:

  
 15 

 NOTICE OF EXERCISE 

 

	TO:	SUPERCONDUCTOR TECHNOLOGIES INC. 

 (1) The undersigned hereby elects to purchase
            Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together
with all applicable transfer taxes, if any. 
 (2) Payment shall take the form of (check applicable box): 

[     ] in lawful money of the United States; or 

[     ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set
forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). 

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: 

 

					
		  	 	  	

 The Warrant Shares shall be delivered to the following DWAC Account Number: 

 

					
		  	 	  	
			
		  	 	  	
			
		  	 	  	

 [SIGNATURE OF HOLDER] 
  

	
	 Name of Investing Entity: 
                                         
                                         
                                         
                                         
                                         

Signature of Authorized Signatory of Investing Entity:           
                                         
                                         
                                         
                    

	Name of Authorized Signatory:                               
                                         
                                         
                                         
                                         
  
	Title of Authorized Signatory:                              
                                         
                                         
                                         
                                         
     
	Date:                                     
                                         
                                         
                                         
                                         
                                         
     

 ASSIGNMENT FORM 

(To assign the foregoing warrant, execute 

this form and supply required information. 

Do not use this form to exercise the warrant.) 

FOR VALUE RECEIVED, [            ] all of or
[            ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to 
  

			
	                                      
                                         
                 whose address is	  	
		
	                                      
                                         
                                         
       .	  	
		
	                                      
                                         
                                         
         	  	
	
	Dated:                     ,
            
		
	                                    
        Holder’s
Signature:                                      
	  	
		
	                                    
         Holder’s
Address:Exhibit
10.90

 

SECURITIES
PURCHASE AGREEMENT

 

This
Securities Purchase Agreement (this “Agreement”) is dated as of October 2, 2015 (the “Execution
Date”), by and between Twinlab Consolidated Holdings, Inc., a Nevada corporation (the “Company”),
and Golisano Holdings LLC, a New York limited liability company (the “Purchaser”).

 

Recitals

 

A.           The
Company and the Purchaser are executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and,
if necessary, Rule 506 of Regulation D (“Regulation D”) as promulgated by the United
States Securities and Exchange Commission (the “Commission”) under the Securities Act.

 

B.           The
Purchaser wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, 88,711,241
shares of common stock (the “Closing Shares”), par value $0.001 per share (the “Common Stock”)
of the Company which constitutes as of immediately following the Closing (as defined below) thirty percent (30%) of the Company’s
issued and outstanding Common Stock and a Common Stock Purchase Warrant (the “Warrant”) to purchase
additional shares of Common Stock in substantially the form attached hereto as Exhibit A. The shares of Common Stock
issuable upon exercise of or otherwise pursuant to the Warrant collectively are referred to herein as the “Warrant
Shares” and together with the Closing Shares, the “Shares.”

 

C.           Contemporaneously
with the execution and delivery of this Agreement, the parties hereto are executing and delivering a Registration Rights Agreement,
substantially in the form attached hereto as Exhibit B (as amended, modified, restated or supplemented from time to
time, the “Registration Rights Agreement”) pursuant to which, among other things, the Company will agree
to provide certain registration rights with respect to the Shares under the Securities Act and the rules and regulations promulgated
thereunder and applicable state securities laws, and will agree to provide certain other rights to the Purchaser.

 

D.           Contemporaneously
with the execution and delivery of this Agreement, the Company, certain of the Company’s stockholders (the “Voting
Stockholders”) and the Purchaser are executing and delivering a Voting Agreement, substantially in the form attached
hereto as Exhibit C (as amended, modified, restated or supplemented from time to time, the “Voting Agreement”),
pursuant to which the Voting Stockholders have agreed to vote their shares of Common Stock in favor of electing the Purchaser’s
nominee to the Company’s Board of Directors and certain other matters.

 

Now,
Therefore, in consideration of the mutual covenants contained
in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the
Company and the Purchaser hereby agree as follows:

 

     

     

    

 

Article
1

DEFINITIONS

 

1.1           Definitions.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms shall have
the meanings indicated in this Section 1.1:

 

“Acquisition”
means the acquisition by the Company of all of the issued and outstanding membership or other equity interests of the Target Company
as contemplated by the Acquisition Agreement.

 

“Acquisition
Agreement” means collectively, (a) the Option Agreement, (b) the Option Notice dated August 13, 2015, executed by
the Company and delivered to the Target Company and (c) the Unit Purchase Agreement dated September 2, 2014 (including the Disclosure
Schedules and Exhibits thereto), as amended, among the Company, the Target Company and its members.

 

“Acquisition
Documents” means the Acquisition Agreement and the annexes and exhibits attached thereto, and any other documents
or agreements executed in connection with the transactions contemplated thereunder.

 

“Action”
means any action, suit, inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation
pending or, to the Company’s Knowledge, threatened in writing against the Company or any of its Subsidiaries or any of their
properties or any officer, director or employee of the Company or any of its Subsidiaries acting in his or her capacity as an
officer, director or employee of the Company or any of its Subsidiaries before or by any federal, state, county, local or foreign
court, arbitrator, governmental or administrative agency, regulatory authority, stock market, stock exchange or trading facility.

 

“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, Controls,
is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405. With
respect to the Purchaser, any investment fund or managed account that is managed on a discretionary basis by the same investment
manager as the Purchaser will be deemed to be an Affiliate of the Purchaser.

 

“Agreement”
has the meaning set forth in the Preamble.

 

“Board
of Directors” means the board of directors of the Company.

 

“Business
Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction
of business.

 

    2 

     

    

 

“Capstone
Agreement” means (a) the Agreement for Limited Waiver of Non-Circumvention Provision, dated as of July 5, 2015 (the
“Capstone Waiver Agreement”), whereby Capstone Financial Group, Inc. ("Capstone"),
for a fee as set forth therein, agreed to provide the Company with a limited waiver of the “Noncircumvention Provision”
(as defined in the Capstone Waiver Agreement) with respect to a particular “Investor” (as defined in the Capstone
Waiver Agreement); and (b) the Compromise Agreement and Release, dated as of May 28, 2015 whereby,
among other things, Capstone granted to the Company three separate contingent call option rights to acquire from Capstone, at
a call option exercise price of $0.01 per share with respect to a number of shares of outstanding shares of Common Stock owned
by Capstone.

 

“Closing”
means the closing of the purchase by the Purchaser and sale by the Company of Shares to the Purchaser pursuant to this Agreement
on the Closing Date as provided in Section 2.1(a) hereof.

 

“Closing
Date” means the date on which the last to be satisfied or waived of the conditions set forth in Sections 2.1,
2.2, 5.1 and 5.2 (other than those to be satisfied at the Closing) shall have been satisfied or waived.

 

“Closing
Shares” has the meaning set forth in the Recitals.

 

“Commission”
has the meaning set forth in the Recitals.

 

“Common
Stock” has the meaning set forth in the Recitals, and also includes any securities into which the Common Stock may
hereafter be reclassified or changed.

 

“Common
Stock Proportional Ownership” means on each date, the ratio, as of such date, of (i) the shares of Common Stock
owned by Purchaser and its Affiliates on such date, to (ii) all shares of Common Stock
which are issued and outstanding on such date. As of the Closing Date, the Purchaser’s Common Stock Proportional Ownership
is 0.30.

 

“Company”
has the meaning set forth in the preamble to this Agreement.

 

“Company
Counsel” means Wilk Auslander LLP.

 

“Company
Deliverables” has the meaning set forth in Section 2.2(a).

 

“Company’s
Knowledge” means with respect to any statement made to the knowledge of the Company, that the statement is based
upon the actual knowledge of the Company’s CEO and any officers of the Company who have responsibility for the matter or
matters that are the subject of the statement, provided, however, that the
CEO and such officers have conducted reasonable investigation and due inquiry of such matter or matters.

 

“Company
Material Adverse Effect” means any state of facts, change, development, event,
effect, condition, occurrence, action or omission that, individually or in the aggregate, has resulted in or would reasonably
be expected to result in (a) a material adverse effect on the results of operations, assets, liabilities, business or financial
condition of the Company and/or its Subsidiaries, taken as a whole, except that any of the following, either alone or in combination,
shall not be deemed a Company Material Adverse Effect: (i) effects caused by changes or circumstances affecting general market
conditions in the U.S. economy or which are generally applicable to the industry in which the Company and/or its Subsidiaries
operates provided that such effects are not borne disproportionately by the Company and/or its Subsidiaries, (ii) effects
resulting from or relating to the announcement or disclosure of the sale of the Securities or other transactions contemplated
by this Agreement, or (iii) effects caused by any event, occurrence or condition resulting from or relating to the taking
of any action in accordance with this Agreement; or (b) any inability of the Company to perform its obligations under this Agreement,
any of the other Golisano Investment Documents or to consummate the Acquisition in accordance with the terms of the Acquisition
Documents.

 

    3 

     

    

 

“Control”
(including the terms “controlling”, “controlled” by or “under common
control with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management
and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

 

“Derivative
Securities” means any securities of the Company which would entitle the holder thereof to acquire at any time shares
of Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

“Disclosure
Materials” means (a) the Disclosure Schedules and (b) the SEC Reports, provided, however, that (i) any information
contained in any part of any SEC Reports shall not be deemed to be an exception to any representation or warranty by the Company
in Section 3.1 unless the relevance of such item as an exception is reasonably apparent on its face and (ii) in no event shall
any risk factor disclosure under the heading “Risk Factors” or disclosure set forth in any “forward looking
statements” disclaimer or other general statements to the extent they are predictive or forward looking in nature that are
included in any part of any SEC Report be deemed to be an exception to any representation or warranty, or, as applicable, a disclosure
for purposes of, any provision in this Agreement.

 

“Disclosure
Schedules” means the disclosure schedules attached to this Agreement.

 

“Disposition”
has the meaning set forth in Section 4.12.

 

“Environmental
Laws” has the meaning set forth in Section 3.1(l).

 

“Evaluation
Date” has the meaning set forth in Section 3.1(v).

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations
promulgated thereunder.

 

"Excluded
Securities" means (a) any shares of Common Stock issued pursuant to the "Qualified Derivative Securities" which
are referred to in the Warrant, (b) any shares of Common Stock issued pursuant to an employee and director stock incentive plan
approved by the Board of Directors and (c) any shares of Common Stock that are issued contemporaneously with the surrender of
outstanding shares by Thomas A. Tolworthy for no consideration.

 

“Execution
Date” has the meaning set forth in the Preamble.

 

“FDA”
has the meaning set forth in Section 3.1(o).

 

    4 

     

    

 

“Future
Equity Issuance” has the meaning set forth in Section 4.14(a).

 

“Future
Equity Issuance Notice” has the meaning set forth in Section 4.14(b).

 

“GAAP”
means U.S. generally accepted accounting principles, as applied by the Company.

 

“Great
Harbor Securities Purchase Agreement” means that certain Stock Purchase Agreement dated October 1, 2015 between
the Company and Great Harbor Capital, LLC, pursuant to which Great Harbor Capital, LLC agreed to purchase 41,379,310 shares of
Common Stock for a purchase price of $12,000,000.

 

“Great
Harbor Equity Financing Documents” means the Great Harbor Securities Purchase Agreement and the annexes and exhibits
attached thereto, and any other documents or agreements executed in connection with such document.

 

“Great
Harbor Equity Financing Transactions” means the transactions contemplated by the Great Harbor Equity Financing Documents.

 

“Golisano
Investment Documents” means this Agreement, the Registration Rights Agreement, the Voting Agreement, the Warrant,
the Irrevocable Transfer Agent Instructions, the annexes and exhibits attached hereto and thereto and any other documents or agreements
executed in connection with the transactions contemplated hereunder.

 

“Governmental
Body” shall mean any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other
jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental
authority of any nature (including any governmental division, department, agency, commission, instrumentality, official, ministry,
fund, foundation, center, organization, unit or body and any court or other tribunal); or (d) self-regulatory organization.

 

“Indemnified
Person” has the meaning set forth in Section 4.8(b).

 

“Intellectual
Property” has the meaning set forth in Section 3.1(r).

 

“Irrevocable
Transfer Agent Instructions” means, with respect to the Company, the Irrevocable Transfer Agent Instructions, in
the form of Exhibit D, executed by the Company and delivered to and acknowledged in writing by the Transfer Agent.

 

“Lien”
means any lien, charge, claim, encumbrance, security interest, priority, right or preferential treatment of any kind, right of
first refusal, preemptive right or other restrictions of any kind.

 

“Material
Contract” means any contract of the Company or any Subsidiary that has been filed or is required to be filed as
an exhibit to the SEC Reports pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K (including, for purposes
hereof, any contracts that are required to be filed as an exhibit to a Form 10).

 

    5 

     

    

 

“Material
Permits” has the meaning set forth in Section 3.1(p).

 

"New Securities”
means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants
to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable
into or exercisable for such equity securities.

 

“New York
Courts” means the state and federal courts sitting in the State of New York.

 

“Option
Agreement” means the Option Agreement dated September 2, 2014 (including the Disclosure Schedules and Exhibits thereto),
as amended by Amendment No.1 dated July 13, 2015, Amendment No. 2 dated July 14, 2015, Amendment No. 3 dated July 15, 2015, Amendment
No. 4 dated July 16, 2015 and Amendment No. 5 dated July 17, 2015, each of which are among the Company, the Target Company and
its members.

 

“Order”
means any charge, order, writ, injunction, judgment, decree, ruling, determination, directive, award or settlement, whether civil,
criminal or administrative and whether formal or informal, applicable to the Company or the Purchaser.

 

“Outside
Date” means November 15, 2015.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Pre-Equity
Issuance Notice” has the meaning set forth in Section 4.14(b).

 

“Principal
Trading Market” means the Trading Market on which the Common Stock is primarily listed on or quoted for trading,
which, as of the date of this Agreement and the Closing Date, shall be the OTC Bulletin Board.

 

“Press
Release” has the meaning set forth in Section 4.6.

 

“Public
Information Failure” has the meaning set forth in Section 4.3(b).

 

“Public
Information Failure Payments” has the meaning set forth in Section 4.3(b).

 

“Purchase
Price” means $25,000,000.

 

“Purchaser”
has the meaning set forth in the preamble to this Agreement.

 

“Purchaser
Deliverables” has the meaning set forth in Section 2.2(b).

 

“Purchaser
Party” has the meaning set forth in Section 4.8(a).

 

“Registration
Rights Agreement” has the meaning set forth in the Recitals.

 

“Regulation
D” has the meaning set forth in the Recitals.

 

    6 

     

    

 

“Reporting
Period” has the meaning set forth in Section 4.3(a).

 

“Required
Approvals” has the meaning set forth in Section 3.1(e).

 

“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“SEC Reports”
has the meaning set forth in Section 3.1(h).

 

“Secretary’s
Certificate” has the meaning set forth in Section 2.2(a)(vii).

 

“Securities”
means the Closing Shares and the Warrant.

 

“Securities
Act” has the meaning set forth in the Recitals.

 

“Shares”
has the meaning set forth in the Recitals.

 

“Short
Sales” include, without limitation, (a) all “short sales” as defined in Rule 200 promulgated
under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges,
forward sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h)
under the Exchange Act) and similar arrangements (including on a total return basis), and (b) sales and other transactions
through non-U.S. broker dealers or foreign regulated brokers.

 

“Solvent”
means the Company (a) owns property whose fair saleable value is greater than the amount required to pay all of the Company’s
liabilities (including contingent liabilities, discounted by the probability of such debts becoming due and payable), (b) is
able to pay all of its liabilities as such liabilities become due and (c) has capital sufficient to carry on its business
and transactions and all business and transactions in which it is about to engage.

 

“Stock
Certificates” has the meaning set forth in Section 2.2(a)(vi).

 

“Subsidiary”
means any entity in which the Company, directly or indirectly, owns capital stock or holds an equity or similar interest.

 

“Target
Company” means Organic Holdings, LLC, a Delaware limited liability company.

 

“Target
Material Adverse Effect” means any state of facts, change, development, event,
effect, condition, occurrence, action or omission that, individually or in the aggregate, has resulted in or would reasonably
be expected to result in a material adverse effect on the results of operations, assets, liabilities, business or financial
condition of the Target Company and/or its Subsidiaries, taken as a whole, except that any of the following, either alone or in
combination, shall not be deemed a Target Material Adverse Effect: (i) effects caused by changes or circumstances affecting
general market conditions in the U.S. economy or which are generally applicable to the industry in which the Target Company and/or
its Subsidiaries operates provided that such effects are not borne disproportionately by the Target Company and/or its Subsidiaries,
(ii) effects resulting from or relating to the announcement or disclosure of the Acquisition or other transactions contemplated
by the Acquisition Agreement, or (iii) effects caused by any event, occurrence or condition resulting from or relating to
the taking of any action in accordance with the Acquisition Agreement or its ability to consummate the transactions contemplated
by the Acquisition Agreement.

 

    7 

     

    

 

“Tolworthy
Share Surrender Transaction” means that Thomas A. Tolworthy shall have surrendered to the Company for no consideration
53,892,009 shares of Common Stock pursuant to a surrender agreement that is in form and substance satisfactory to Purchaser in
its sole discretion.

 

“Trading
Affiliate” has the meaning set forth in Section 3.2(h).

 

“Trading
Day” means (i) a day on which the Common Stock is listed or quoted and traded on its Principal Trading Market
(unless the Principal Trading Market is the OTC Bulletin Board or the “pink sheets”), or (ii) if the Common Stock
is not listed on a Trading Market (other than the OTC Bulletin Board or the OTC QB, OTC QX or “pink sheets” tier of
the OTC Markets Group, Inc.), a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTC
Bulletin Board, or (iii) if the Common Stock is not quoted on any Trading Market (other than the OTC QB, OTC QX or “pink
sheets” tier of the OTC Markets Group, Inc.), a day on which the Common Stock is quoted in the over-the-counter market as
reported by the OTC QB, OTC QX or “pink sheets” tier of the OTC Markets Group, Inc. (or any similar organization or
agency succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed
or quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day shall mean a Business Day.

 

“Trading
Market” means whichever of the New York Stock Exchange, the NYSE-MKT, the Nasdaq Global Select Market, the Nasdaq
Global Market, the Nasdaq Capital Market, the OTC Bulletin Board, the OTC QB, OTC QX or “pink sheets” tier of the
OTC Markets Group, Inc. (or any similar organization or agency succeeding to its functions of reporting prices) on which the Common
Stock is listed or quoted for trading on the date in question.

 

“Transaction
Documents” means the Acquisition Documents, the Great Harbor Equity Financing Documents and the Golisano Investment
Documents.

 

“Transactions”
means collectively (a) the Acquisition, (b) the Great Harbor Equity Financing Transaction, (c) the Tolworthy Share Surrender
Transaction, (d) the transactions contemplated hereby and (e) the payment of fees and expenses related thereto and hereto. 

 

“Transfer
Agent” means West Coast Stock Transfer, Inc., or any successor transfer agent for the Company.

 

“Voting
Agreement” has the meaning set forth in the Recitals.

 

“Voting
Stockholders” has the meaning set forth in the Recitals.

 

“Warrant”
has the meaning set forth in the Recitals.

 

“Warrant
Shares” has the meaning set forth in the Recitals.

 

    8 

     

    

 

Article
2

 

PURCHASE
AND SALE

 

2.1          Closing.

 

(a)          Purchase
and Sale. Subject to the terms and conditions set forth in this Agreement, the Purchaser agrees to purchase from the Company,
and the Company agrees to sell to the Purchaser, the Securities at the Purchase Price.

 

(b)          Closing.
The Closing of the purchase and sale of the Securities shall take place remotely by exchange of documents delivered by facsimile
transmission or other electronic means as the parties may mutually agree.

 

(c)          Purchase
Price Payment; Issuance of Stock Certificate. On the Closing Date, (i) the Purchaser shall wire an amount equal to the
Purchase Price, in United States dollars and in immediately available funds, by wire transfer to the Company’s account,
as set forth in instructions previously provided to the Purchaser, and (ii) the Company shall irrevocably instruct the Transfer
Agent to deliver to the Purchaser one or more stock certificates, free and clear of all restrictive and other legends except as
expressly provided in Section 4.1(b) hereof or in the Golisano Investment Documents, evidencing the Closing Shares and the
Company shall issue to the Purchaser the Warrant executed on behalf of the Company by an authorized officer of the Company and
registered in the name of the Purchaser.

 

2.2          Closing
Deliveries.

 

(a)          Company
Deliverables. On or prior to the Closing, the Company shall issue, deliver or cause to be delivered to the Purchaser the following
(the “Company Deliverables”):

 

(i)          this
Agreement, duly executed by the Company;

 

(ii)         the
Warrant duly executed by the Company;

 

(iii)        the
Voting Agreement, duly executed by the Company and the Voting Stockholders;

 

(iv)        the
Registration Rights Agreement, duly executed by the Company;

 

(v)         the
documentary evidence required by Sections 5.1(g), 5.1(h), 5(i), 5(j), and 5.1(k);

 

(vi)        a
copy of the duly executed Irrevocable Transfer Agent Instructions delivered to the Transfer Agent, relating to the issuance of
stock certificates, free and clear of all restrictive and other legends except as provided in Section 4.1(b) hereof or the
Golisano Investment Documents, evidencing the Closing Shares subscribed for by the Purchaser hereunder to be registered in the
Purchaser’s name (the “Stock Certificate”) with the original Stock Certificate to be delivered
to the address set forth in Section 6.3 following the Closing;

 

    9 

     

    

 

(vii)       a
certificate of the Secretary of the Company (the “Secretary’s Certificate”), dated as of the Closing
Date, (a) certifying the resolutions adopted by the Board of Directors of the Company or a duly authorized committee thereof
approving the transactions contemplated by this Agreement and the other Transaction Documents and the issuance of the Securities,
(b) certifying the current versions of the articles of incorporation, as amended, and bylaws of the Company and (c) certifying
as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company,
in the form attached hereto as Exhibit E;

 

(viii)      a
certificate evidencing the formation and good standing of the Company issued by the Secretary of State of the State of Nevada,
as of a date within five (5) days of the Closing Date;

 

(ix)         a
certificate evidencing the Company’s qualification as a foreign corporation and good standing issued by the Secretary of
State of the State of New York as of a date within five days of the Closing Date; and

 

(xi)         a
certified copy of the Articles of Incorporation, as certified by the Secretary of State of the State of Nevada, as of a date within
ten (10) days of the Closing Date;

 

(xii)        a
compliance certificate, dated as of the Closing Date and signed by the Company’s Chief
Executive Officer, certifying to the fulfillment of the conditions specified in Sections 5.1(a), (b), (c), (d), (e), (f), (g),
(h), (i), (j), (k), (l) and (m), provided that (m) may be based on the CEO’s actual knowledge, in substantially the form
attached hereto as Exhibit F; and

 

(xiii)       a
legal opinion of Company Counsel, dated as of the Closing Date and in substantially the form attached hereto as Exhibit
G, executed by such counsel and addressed to the Purchaser.

 

(b)          Purchaser
Deliverables. On or prior to the Closing, the Purchaser shall deliver or cause to be delivered to the Company the following
(the “Purchaser Deliverables”):

 

(i)          this
Agreement, duly executed by the Purchaser;

 

(ii)         the
Registration Rights Agreement duly executed by the Purchaser;

 

(iii)        the
Voting Agreement duly executed by the Purchaser; and

 

(iv)        the
Purchase Price in United States dollars and in immediately available funds, by wire transfer to the Company’s account as
previously provided to the Purchaser.

 

    10 

     

    

 

Article
3

REPRESENTATIONS AND WARRANTIES

 

3.1          Representations
and Warranties of the Company. The Company hereby represents and warrants as of Execution Date and the Closing Date (except
for the representations and warranties that speak as of a specific date, which shall be made as of such date), to the Purchaser
that, except as disclosed in the Disclosure Materials, which shall be deemed a part hereof and shall qualify only the representations
made by the Company herein which specifically reference the applicable Disclosure Materials and then only to the extent of the
applicable disclosure made in such Disclosure Materials:

 

(a)          Subsidiaries.
The Company has no direct or indirect Subsidiaries other than Twinlab Consolidation Corporation, a Delaware corporation, Twinlab
Holdings, Inc., a Michigan corporation, Twinlab Corporation, a Delaware corporation, ISI Brands Inc., a Michigan corporation,
NutraScience Labs, Inc., a Delaware corporation, and NutraScience Labs IP Corporation, a Delaware corporation. Except as set forth
on Section 3.1(a) of the Disclosure Schedules, the Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary free
and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are
validly issued and are fully paid, non-assessable, free of preemptive and similar rights to subscribe for or purchase securities
and there are no commitments for the purchase or sale of, and no options, warrants or other rights to subscribe for or
purchase, any securities of any such Subsidiary.

 

(b)          Organization
and Qualification. The Company and each of its Subsidiaries is an entity duly incorporated, validly existing and in good standing
under the laws of the state of its incorporation, with the requisite corporate power and authority to own or lease and use its
properties and assets and to carry on its business as currently conducted. Neither the Company nor any of its Subsidiaries is
in violation of any of the provisions of its articles of incorporation or certificate of incorporation or bylaws or other organizational
documents. The Company and each of its Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such
qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have a
Company Material Adverse Effect, and no Action has been instituted, is pending, or, to the Company’s Knowledge, has been
threatened in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.

 

(c)          Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by each of the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder
and thereunder. The execution and delivery of each of the Transaction Documents to which the Company is a party and the consummation
by it of the transactions contemplated hereby and thereby (including, but not limited to, the sale and delivery of the Securities)
have been duly authorized by all necessary corporate action on the part of the Company, and no further corporate action is required
by the Company, its Board of Directors or its stockholders in connection therewith other than in connection with the Required
Approvals. Each of the Transaction Documents to which it is a party has been (or upon delivery will have been) duly executed by
the Company and is, or when delivered in accordance with the terms hereof, will, constitute the legal, valid and binding obligation
of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement
of, creditors’ rights and remedies or by other equitable principles of general application or insofar as indemnification
and contribution provisions may be limited by applicable law.

 

    11 

     

    

 

(d)          No
Conflicts. The execution, delivery and performance by the Company of this Agreement and all of the other Transaction Documents
to which it is a party and the consummation by the Company of the transactions contemplated hereby or thereby (including, without
limitation, the issuance of the Securities, the issuance of shares of Common Stock pursuant to the Great Harbor Equity Financing
Transaction Documents and the consummation of the Acquisition) do not and will not (i) conflict with or violate any provisions
of the Company’s or any Subsidiaries’ articles of incorporation, certificates of incorporation or bylaws or otherwise
result in a violation of the organizational documents of the Company or any Subsidiary, (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon
any of the properties or assets of the Company or any Subsidiary or give to others any rights of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) of, any Material Contract or (iii) subject to the Required
Approvals, result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any
court or governmental authority to which the Company or any Subsidiary is subject (including federal and state securities laws
and regulations and the rules and regulations, assuming the correctness of the representations and warranties made by the Purchaser
herein, of any self-regulatory organization to which the Company or its securities are subject, including all applicable Trading
Markets), or by which any property or asset of the Company or any Subsidiary is bound or affected), except in the case of clause
(iii) would not individually or in the aggregate have a Company Material Adverse Effect.

 

(e)          Filings,
Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents (including the issuance
of the Securities), other than (i) the filing with the Commission of one or more Registration Statements in accordance with
the requirements of the Registration Rights Agreement, (ii) filings required by applicable state securities laws, (iii) the
filing, if necessary, of a Notice of Sale of Securities on Form D with the Commission under Regulation D of the Securities
Act, (iv) the filing of any requisite notices and/or application(s) to the Principal Trading Market for the issuance and
sale of the Shares and the listing of the Shares for trading or quotation, as the case may be, thereon in the time and manner
required thereby, (v) the filings required in accordance with Section 4.6 of this Agreement and (vi) those set
forth in Section 3.1(e) of the Disclosure Schedules, all of which have been made or obtained prior to the Execution Date and copies
of which have been provided to Purchaser (collectively, the “Required Approvals”).

 

    12 

     

    

 

(f)          Issuance
of the Securities.

 

(i)          The
Securities have been duly authorized and, when issued and paid for in accordance with the terms of the Golisano Investment Documents,
will be duly and validly issued, fully paid and non-assessable and free and clear of all Liens, other than restrictions on transfer
provided for in the Golisano Investment Documents or imposed by applicable securities laws, and shall not be subject to preemptive
or similar rights. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock
which may be issued as Warrant Shares under the Warrant.

 

(ii)         Assuming
the accuracy of the representations and warranties of the Purchaser in this Agreement, the Securities will be issued in compliance
with all applicable federal and state securities laws.

 

(g)          Capitalization.

 

(i)           The
authorized capital stock of the Company is as follows:

 

(A)         The
authorized capital stock of the Company consists of (1) 5,000,000,000 shares of Common Stock, of which 219,505,594 shares are
issued and outstanding, and (2) 5,000,000 shares of preferred stock, par value $0.0001 (“Preferred Stock”)
of which no shares are outstanding.

 

(B)         Immediately
following the Closing after giving effect to the Transactions, the authorized capital stock of the Company shall consist of (1)
5,000,000,000 shares of Common Stock, of which 295,704,136 shares will be issued and outstanding, and (2) 5,000,000 shares of
Preferred Stock, of which no shares will be issued and outstanding.

 

(ii)  (A) all
of the issued and outstanding shares of capital stock of the Company are and immediately following the Closing will have been
duly authorized, validly issued, fully paid and non-assessable, (B) all of the issued and outstanding shares of capital stock
of the Company are and immediately following the Closing will have been issued in compliance with all applicable federal and state
securities laws, (C) none of the issued and outstanding shares of capital stock of the Company have been and immediately following
the Closing will have been issued in violation of any agreement, arrangement or commitment to which the Company or any of its
Affiliates is a party or is subject to or in violation of any preemptive or similar rights of any Person. The issued and outstanding
shares of capital stock in the Company immediately following the Closing will be held by the stockholders in the amounts shown
in Section 3.1(g)(ii) of the Disclosure Schedules.

 

(iii)        Section
3.1(g)(iii) of the Disclosure Schedules sets forth, as of immediately following the Closing after giving effect to
the transactions contemplated by this Agreement and the other Transaction Documents, all outstanding or authorized stock options
and warrants relating to the capital stock of the Company. Except as set forth on Section 3.1(g)(iii) of the Disclosure
Schedules, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any
Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements
by which the Company or any Subsidiary is or may become bound to issue additional shares of capital stock or any other interest
in the Company or such Subsidiary, as applicable. Any warrants shown on Section 3.1(g)(iii) of the Disclosure Schedules
as having been exercised are of no further force or effect, and the named holder of such exercised warrants has no further rights
under such warrants.

 

    13 

     

    

 

(iv)        The
issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person
(other than the Purchaser) and will not result in a right of any holder of Company securities to adjust the exercise, conversion,
exchange or reset price under any of such securities. Except as set forth in the Great Harbor Securities Purchase
Agreement, no Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate
in the transactions contemplated by the Golisano Investment Documents that have not been effectively waived as of the Closing.

 

(v)         Except
for the Golisano Investment Documents and except as set forth on Section 3.1(g)(v) of the Disclosure Schedules, there are
no voting trusts, stockholder agreements, proxies or other agreements, understandings or obligations in effect with respect to
the voting, transfer or sale (including any rights of first refusal, rights of first offer or drag-along rights), issuance (including
any pre-emptive or anti-dilution rights), redemption or repurchase (including any put or call or buy-sell rights), or registration
(including any related lock-up or market standoff agreements) of any shares of capital stock or other securities of the Company.

 

(vi)        Except
as set forth in Section 3.1(g)(vi) of the Disclosure Schedules, (A) there are no outstanding debt securities, notes,
credit agreements, credit facilities or other agreements, documents or instruments evidencing indebtedness of the Company or by
which the Company is or may become bound; (B) there are no financing statements securing obligations in any material amounts,
either singly or in the aggregate, filed in connection with the Company; (C) there are no outstanding securities or instruments
of the Company which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or
arrangements by which the Company is or may become bound to redeem a security of the Company; (D)  the Company does not have
any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement; (E) the Company
does not have any agreements or arrangements pursuant to which Company warrants or other securities of the Company would be adjusted
based on failure to meet any earnings or EBITDA targets; and (F) the Company has no liabilities or obligations required to
be disclosed in the SEC Reports (including, for purposes hereof, any liabilities that are required to be disclosed in a Form 10-K)
but not so disclosed in the SEC Reports except liabilities or obligations incurred in the ordinary course of business and consistent
with past practice since the date of the last balance sheet included in the SEC Reports.

 

(h)          SEC
Reports.

 

(i)          The
Company has filed all reports, schedules, forms, statements and other documents required to be filed by it under the Exchange
Act, including pursuant to Section 13(a) or 15(d) thereof, for twelve (12) months preceding and including the last day prior
to the Execution Date or such shorter period as the Company was required by law or regulation to file such material (the foregoing
materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein
as the “SEC Reports”) on a timely basis or has received a valid extension of such time of filing and
has filed any such SEC Reports prior to the expiration of any such extension.

 

    14 

     

    

 

(ii)         As
of their respective filing dates, or to the extent corrected by a subsequent amendment, the SEC Reports complied in all material
respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the Commission promulgated
thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which
they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act.

 

(iii)        Each
of the Material Contracts to which the Company or any Subsidiary is a party or to which the property or assets of the Company
or any of its Subsidiaries are subject has been filed (or incorporated by reference) as an exhibit to the SEC Reports. Without
limiting the foregoing, to the extent not filed as an exhibit the Company has provided the Purchaser with true, correct and complete
copies of all waivers and amendments to all debt securities, notes, credit agreements, credit facilities or other agreements,
documents or instruments evidencing indebtedness of the Company or by which the Company is or may become bound. The description
of the Material Contracts, documents or other agreements contained in the SEC Reports (as the case may be) reflect in all material
respects the terms of the underlying contract, document or other agreement. Each such Material Contract, document or other
agreement is in full force and effect and is valid and enforceable by and against the Company or the Subsidiaries, as applicable,
in accordance with its terms. Except as described in the SEC Reports, neither the Company nor any of its Subsidiaries is
in default in the observance or performance of any term or obligation to be performed by it under any such agreement, and no event
has occurred which with notice or lapse of time or both would constitute such a default, in any such case which default or event,
individually or in the aggregate, would result in a Company Material Adverse Effect.

 

(iv)        To
the Company’s Knowledge there is no event occurring on or prior to the Closing Date (other than the transactions contemplated
by the Transaction Documents) that requires the filing of a Current Report on Form 8-K after the Closing.

 

(i)          Financial
Statements. The consolidated financial statements of the Company and its consolidated Subsidiaries included in the SEC Reports
comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect
thereto as in effect at the time of filing. Such consolidated financial statements have been prepared in accordance with GAAP
applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or
the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present
in all material respects the financial position of the Company and its consolidated Subsidiaries taken as a whole as of and for
the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
to normal, year-end audit adjustments which are not material either individually or in the aggregate.

 

    15 

     

    

 

(j)          Tax
Matters. The Company and each of its Subsidiaries (i) has prepared and filed all foreign, federal and state income and
all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes
and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports
and declarations, except those being contested in good faith, with respect to which adequate reserves have been set aside on the
books of the Company or the applicable Subsidiary and (iii) has set aside on its books provisions reasonably adequate for
the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply, except where
the failure to so pay or file or set aside provisions for any such tax, assessment, charge or return would not have or reasonably
be expected to have a Company Material Adverse Effect.

 

(k)          Material
Changes. Since March 31, 2015, except as specifically disclosed in the SEC Reports, (i) there have been no events, occurrences
or developments, either individually or in the aggregate that have had or would reasonably be expected to have a Company Material
Adverse Effect, (ii) neither the Company nor any Subsidiary has incurred any material liabilities (contingent or otherwise)
other than (A) trade payables, accrued expenses and other liabilities incurred in the ordinary course of business consistent
with past practice and (B) liabilities not required to be reflected in the Company’s consolidated financial statements
pursuant to GAAP or to be disclosed in filings made with the Commission, (iii) the Company has not materially altered its
method of accounting or the manner in which it keeps its accounting books and records, (iv) the Company has not declared
or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements
to purchase or redeem any shares of its capital stock (other than in connection with repurchases of unvested stock issued to employees
of the Company), (v) the Company has not issued any equity securities to any officer, director or Affiliate, except Common
Stock issued in the ordinary course pursuant to existing Company stock option or stock purchase plans or executive and director
corporate arrangements disclosed in the SEC Reports and (vi) there has not been any material change or amendment to, or any
waiver of any material right under, any Material Contract under which the Company or any Subsidiary or any of their respective
assets is bound or subject. The Company does not have pending before the Commission any request for confidential treatment of
information. Except for the issuance of the Securities contemplated by this Agreement, no event, liability or development has
occurred or exists with respect to the Company or its business, properties, operations or financial condition that would be required
to be disclosed by the Company under applicable securities laws at the time this representation is made that has not been publicly
disclosed in the SEC Reports.

 

(l)          Environmental
Matters. The Company (i) is not in violation of any statute, rule, regulation, decision or order of any governmental
agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or
relating to the protection or restoration of the environment or human exposure to hazardous or toxic substances (collectively,
“Environmental Laws”), (ii)  to the Company’s Knowledge does not own or operate any real
property contaminated with any substance that is in violation of any Environmental Laws, (iii) is not liable for any off-site
disposal or contamination pursuant to any Environmental Laws, and (iv) to the Company’s Knowledge is not subject to
any claim relating to any Environmental Laws; which violation, contamination, liability or claim has had or would reasonably be
expected to have a Company Material Adverse Effect; and there is no pending or, to the Company’s Knowledge, threatened investigation
that might lead to such a claim.

 

    16 

     

    

 

(m)          Litigation.
There is no Action which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction
Documents or the Securities, (ii) except as set forth on Section 3.1(m)(ii) of the Disclosure Schedules, involves
a claim of violation of or liability under any federal, state, local or foreign laws governing the operations of the Company and
its Subsidiaries, including without limiting the generality of the foregoing, laws regulating the protection of human health,
including without limiting the generality of the foregoing, laws relating to the manufacture, processing, packaging, labeling,
marketing, distribution, use, inspection, treatment, storage, disposal, transport or handling of the Company’s or its Subsidiaries’
products, and regulated or hazardous substances, as well as all authorizations, codes, decrees, demands or demand letters, injunctions,
judgments, licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved
thereunder, all as may be in effect from time to time and all successors, replacements and expansions thereof, (iii) involves
injury to or death of any person arising from or relating to any of the products of the Company or its Subsidiaries or (iv) could,
if there were an unfavorable decision, either individually or in the aggregate, have or reasonably be expected to result in a
Company Material Adverse Effect. During the past five years, neither the Company nor any Subsidiary, nor to the Company’s
Knowledge any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability
under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the Company’s
Knowledge there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former
director or officer of the Company. During the past five years, the Commission has not issued any stop order or other order suspending
the effectiveness of any registration statement filed by the Company under the Exchange Act or the Securities Act.

 

(n)          Employment
Matters. No material labor dispute exists or, to the Company’s Knowledge, is imminent with respect to any of the employees
of the Company which would have or reasonably be expected to result in a Company Material Adverse Effect. None of the Company’s
or any Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company,
and neither the Company nor any Subsidiary is a party to a collective bargaining agreement, and the Company believes that its
relationship with its employees is good. No executive officer of the Company (as defined in Rule 501(f) of the Securities Act)
has notified the Company or any of its Subsidiaries that such officer intends to leave the Company or any such Subsidiary or otherwise
terminate such officer’s employment with the Company or any such Subsidiary. To the Company’s Knowledge, no executive
officer or key employee of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any
employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other
contract or agreement or any restrictive covenant in favor of any third party, and to the Company’s Knowledge, the continued
employment of each such executive officer or key employee does not subject the Company or any Subsidiary to any liability with
respect to any of the foregoing matters, except, in each case, matters that, individually or in the aggregate, would not reasonably
be expected to result in a Company Material Adverse Effect. The Company and each Subsidiary is in compliance with all U.S. federal,
state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment
and wages and hours, except where the failure to be in compliance would not, individually or in the aggregate, result in, or reasonably
be expected to result in, a Company Material Adverse Effect.

 

    17 

     

    

 

(o)          Compliance.
Neither the Company nor any of its Subsidiaries (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any of its Subsidiaries
under or a violation of), any indenture, loan or credit agreement or any other Material Contract (whether or not such default
or violation has been waived), (ii) is not in violation of any order of any court, arbitrator or governmental body having
jurisdiction over the Company or any Subsidiary or their respective properties or assets and (iii) is or has been in violation
of, or, except as set forth in Section 3.1(o) of the Disclosure Schedules, in receipt of notice that it is in violation
of, any statute, rule or regulation of any governmental authority applicable to the Company, including without limitation, all
applicable rules and regulations of the Food and Drug Administration (the “FDA”), and all applicable
laws, statutes, ordinances, rules or regulations (including, without limitation, the Federal Food, Drug and Cosmetic Act of 1938,
as amended and similar foreign laws and regulations) enforced by the FDA or equivalent foreign authorities, except in each case
as would not, individually or in the aggregate, have or reasonably be expected to result in a Company Material Adverse Effect.

 

(p)          Regulatory
Permits. The Company and each of its Subsidiaries possesses all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct its business as described in the SEC Reports, including
without limitation the FDA, except where the failure to possess such permits, individually or in the aggregate, has not had and
would not have or would not reasonably be expected to result in a Company Material Adverse Effect (“Material Permits”).
Neither the Company, nor any Subsidiary has received any notice of Actions relating to the revocation or modification of any such
Material Permits and, to the Company’s Knowledge, there are no facts or circumstances that the Company or any Subsidiary
would reasonably expect to give rise to the revocation or modification of any Material Permits.

 

(q)          Title
to Assets. The Company and each of its Subsidiaries has good and marketable title to all real property and tangible personal
property owned by it which is material to the business of the Company and the Subsidiaries, in each case free and clear of all
Liens except liens of the Company’s senior and subordinated lenders as disclosed in the SEC Reports and except such as do
not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of
such property by the Company and its Subsidiaries and except for Liens for the payment of federal, state or other taxes for which
appropriate reserves have been made in accordance with GAAP and the payment of which is not delinquent or subject to penalties.
Any real property and facilities held under lease by the Company or any Subsidiary are held by it under valid, subsisting and
enforceable leases with such exceptions as are not material and do not interfere with the use made of such property and buildings
by the Company and its Subsidiaries.

 

    18 

     

    

 

(r)          Intellectual
Property. The Company and each of its Subsidiaries owns, possesses, licenses or has other rights to use all foreign and domestic
patents, patent applications, trade and service marks, trade and service mark applications and registrations, trade names, copyrights,
licenses, inventions, trade secrets, technology, know-how and other intellectual and proprietary rights and processes (collectively,
the “Intellectual Property”) necessary or material for the conduct of its businesses as now conducted
as described in the SEC Reports and, with respect to material activities, as now contemplated
to be conducted as described in the SEC Reports and which the failure to so own, possess, license or have other rights
to use would not have or reasonably be expected to result in a Company Material Adverse Effect. Except where any such violations
or infringements would not have a Company Material Adverse Effect, (i) to the Company’s Knowledge, the Company’s
or its Subsidiaries’ use of any such Intellectual Property in the conduct of its business as presently conducted as described
in the SEC Reports and, with respect to material activities, as now contemplated to be conducted
as described in the SEC Reports does not violate or infringe upon the patent, trademark, copyright, trade secret or other
proprietary rights of any third parties; (ii) to the Company’s Knowledge, there is no infringement by third parties
of any such Intellectual Property; (iii) there is no Action challenging the Company’s or any Subsidiary’s rights
in or to any such Intellectual Property; (iv) there is no Action challenging the validity or scope of any such Intellectual
Property; and (v) there is no Action that the Company or any Subsidiary infringes or otherwise violates any patent, trademark,
copyright, trade secret or other proprietary rights of other. There is no pending or, to the Company’s Knowledge, threatened
Action challenging the Company’s or any Subsidiary’s rights in or to any Intellectual Property, or challenging inventorship,
validity or scope of any such Intellectual Property. The Company and each of its Subsidiaries have taken reasonable security measures
to protect the secrecy, confidentiality and value of all of its and its Subsidiaries’ Intellectual Property, except where
failure to do so would not, individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect.
None of the technology employed by the Company or any of its Subsidiaries has been obtained or is being used by the Company or
any Subsidiary in violation of any contractual obligation binding on the Company or any Subsidiary or, to the Company’s
Knowledge, any of its or its Subsidiaries’ officers, directors or employees or otherwise in violation of the rights of any
Person, which violations would have or would reasonably be expected to have a Company Material Adverse Effect.

 

(s)          Insurance.
The Company and each of its Subsidiaries is insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as the Company believes to be prudent in the businesses and locations in which the Company and its Subsidiaries
are engaged. Neither the Company nor any Subsidiary has received any notice of cancellation of any such insurance, nor to the
Company’s Knowledge will it be unable to renew its existing insurance coverage for the Company or any Subsidiary as and
when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without
a significant increase in cost.

 

    19 

     

    

 

(t)          Acquisition;
Great Harbor Equity Financing; and Solvency.

 

(i)          A
true, complete and correct executed copy of the Acquisition Documents and the Great Harbor Equity Financing Documents have been
provided to the Purchaser. Except for any amendments or modifications as have been approved in writing by the Purchaser, the Acquisition
Documents nor the Great Harbor Equity Financing Documents have been amended or modified, no such amendment or modification is
contemplated, there are no side letters or other agreements, contracts or arrangements related to Acquisition or the Great Harbor
Equity Financing Transactions other than as expressly set forth therein. The Acquisition Agreement and the Great Harbor Equity
Financing Documents are in full force and effect and are the legal, valid, binding and enforceable obligations of the Company
and, to the Company’s Knowledge, each of the other parties thereto, except as such enforceability may be limited by bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws of general application relating to or affecting
creditors’ rights generally and subject to general equitable principles (whether considered in a proceeding in equity or
at law). There are no conditions or other contingencies related to the transactions contemplated by the Acquisition Agreement
or the Great Harbor Equity Financing Documents other than as expressly set forth therein. No event has occurred that, with or
without notice, lapse of time or both, would or would reasonably be expected to constitute a default or breach on the part of
the Company or, to the Company’s Knowledge, any other party thereto under the Acquisition Agreement or the Great Harbor
Equity Financing Documents.

 

(ii)         To
the Company’s Knowledge all of the representations and warranties made in the Acquisition Agreement by the Target and those
Persons owning equity in the Target are true, correct and complete in all respects.

 

(iii)        Assuming
the satisfaction of the conditions set forth in Article 5 of this Agreement, the Company has no reason to believe that
any condition to the Closing will not be satisfied. Assuming the satisfaction of the conditions set forth in Article 5
of this Agreement the Company will have as of the Closing Date funds sufficient to pay the purchase price due the Persons holding
equity interests in the Target.

 

(iv)        On
the Closing Date and immediately after the consummation of the Transactions the Company and its Subsidiaries will be Solvent.

 

(u)          Transactions
With Affiliates and Employees. Except as set forth in the SEC Reports, none of the executive officers or directors of the
Company or any Subsidiary and, to the Company’s Knowledge, none of the employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors) that
would be required to be disclosed pursuant to Item 404 of Regulation S-K promulgated under the Securities Act.

 

    20 

     

    

 

(v)         Sarbanes-Oxley;
Internal Accounting Controls. Except as disclosed below in this Section 3.1(v), the Company and the Subsidiaries are in compliance
with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the Execution Date, and any
and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of Execution Date and
as of the Closing Date.  The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to
provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization,
and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action
is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries that are designed to ensure that
information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed,
summarized and reported, within the time periods specified in the Commission’s rules and forms. The Company’s certifying
officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and its Subsidiaries as of
the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the “Evaluation
Date”). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions
of the certifying officers that at the end of the period covered by that report, such disclosure controls and procedures were
not effective. This was due to the Company's lack of documentation or testing and correction procedures of current internal control
procedures. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term
is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or are reasonably likely to
materially affect, the internal control over financial reporting of the Company and its Subsidiaries except that the Company has
engaged an experienced public accountant to assist it in assessing the Company's controls and financials and consulted with a
Sarbanes-Oxley consultant in order to assess the Company's timeline for full compliance.

 

(w)          Certain
Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company or any Subsidiary to any person
or entity as a result of the transactions contemplated by this Agreement or any of the other Transaction Documents, no Person
will have any valid right, interest or claim against or upon the Company or the Purchaser for any commission, fee or other compensation
pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company. The Company shall indemnify,
pay, and hold the Purchaser harmless against, any liability, loss or expense (including, without limitation, reasonable attorneys’
fees and out-of-pocket expenses) arising in connection with any such right, interest or claim.

 

(x)          Private
Placement. Assuming the accuracy of the Purchaser’s representations and warranties set forth in Section 3.2 of
this Agreement (without giving effect to any materiality qualifiers therein), no registration under the Securities Act is required
for the offer and sale of the Securities by the Company to the Purchaser under the Golisano Investment Documents.

 

(y)          Registration
Rights. Except as set forth in Section 3.1(y) of the Disclosure Schedules, no Person has any right to cause the Company
to effect the registration under the Securities Act of any securities of the Company. None of the Persons listed on Section
3.1(y) of the Disclosure Schedules has piggyback or other registration rights which would entitle them to have the shares
of Common Stock held by them registered under a registration statement that the Company is required to file with the Commission
for the Purchaser pursuant to the Registration Rights Agreement.

 

(z)          No
Directed Selling Efforts or General Solicitation. Neither the Company nor any Person acting on its behalf has conducted any
“general solicitation” or “general advertising” (as those terms are used in Regulation D) in connection
with the offer or sale of any of the Securities.

 

    21 

     

    

 

(aa)         No
Integrated Offering. Assuming the accuracy of the Purchaser’s representations and warranties set forth in Section 3.2
(without giving effect to any materiality qualifiers therein), except as disclosed in the SEC Reports and except for the Great
Harbor Equity Financing Transactions, neither the Company nor any Person acting on its behalf has, directly or indirectly, at
any time within the past six (6) months, made any offers or sales of any Company security or solicited any offers to buy any security
under circumstances that would (i) eliminate the availability of the exemption from registration under Regulation D
under the Securities Act in connection with the offer and sale by the Company of the Securities as contemplated hereby or (ii) cause
the offering of the Securities pursuant to the Transaction Documents to be integrated with prior offerings by the Company for
purposes of any applicable law, regulation or shareholder approval provisions, including, without limitation, under the rules
and regulations of any Trading Market on which any of the securities of the Company are listed or designated.

 

(bb)         Disclosure.
All disclosure furnished by or on behalf of the Company to the Purchaser regarding the Company, its business and the transactions
contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light
of the circumstances under which they were made, not misleading. The Company acknowledges and agrees that the Purchaser has not
made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set
forth in Section 3.2 hereto.

 

(cc)         Listing
and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the
Company has taken no action designed to, or which to the Company’s Knowledge is likely to have the effect of, terminating
the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission
is contemplating terminating such registration. The Company has not, in the 12 months preceding the Execution Date, received written
notice from any Trading Market on which the Common Stock is listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will
not in the foreseeable future continue to be in compliance with all listing and maintenance requirements of the Principal Trading
Market.

 

(dd)         Subsidiary
Rights. The Company or one of its Subsidiaries has the unrestricted right to vote, and (subject to limitations imposed by
applicable law) to receive dividends and distributions on, all capital securities of its Subsidiaries as owned by the Company
or such Subsidiary.

 

(ee)         Investment
Company. The Company is not, and is not an Affiliate of, and immediately following the Closing, will not be an “investment
company” within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in
a manner so that it will not become an “investment company” subject to registration under the Investment Company Act
of 1940, as amended.

 

    22 

     

    

 

(ff)         Application
of Takeover Protections; Rights Agreements. The Company and the Board of Directors have taken all necessary action, if any,
in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under
a rights agreement) or other similar anti-takeover provision under the Company’s charter documents or the laws of the State
of Nevada that is or could become applicable to the Purchaser as a result of the Purchaser and the Company fulfilling their obligations
or exercising their rights under the Transaction Documents, including, without limitation, the Company’s issuance of the
Securities and the Purchaser’s ownership of the Securities. The Company has not adopted a stockholder rights plan or similar
arrangement relating to accumulations of beneficial ownership of Common Stock or a change in control of the Company.

 

(gg)         Off
Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company and an unconsolidated
or other off balance sheet entity that is required to be disclosed by the Company in its SEC Reports (including, for purposes
hereof, any that are required to be disclosed in a Form 10) and is not so disclosed or that otherwise would have or could be reasonably
expected to have a Company Material Adverse Effect.

 

(hh)         Acknowledgment
Regarding the Purchaser’s Purchase of Securities. The Company acknowledges and agrees that the Purchaser is acting solely
in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that the Purchaser is not acting as a financial advisor or fiduciary of the Company
(or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice
given by the Purchaser or its representatives or agents in connection with the Transaction Documents and the transactions contemplated
thereby is merely incidental to the Purchaser’s purchase of the Securities.

 

(ii)          Foreign
Corrupt Practices. Neither the Company nor the Subsidiaries, nor to the Company’s Knowledge, any agent or other person
acting on behalf of the Company or any of the Subsidiaries, has: (i) directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment
to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on
its behalf of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision
of the Foreign Corrupt Practices Act of 1977, as amended

 

3.2          Representations
and Warranties of the Purchaser. The Purchaser hereby represents and warrants as of Execution Date and as of the Closing Date
to the Company as follows:

 

    23 

     

    

 

(a)          Organization;
Authority. The Purchaser is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization with the requisite limited liability company power and authority to enter into and to consummate the transactions
contemplated by the Golisano Investment Documents to which it is a party and otherwise to carry out its obligations hereunder
and thereunder. The execution, delivery and performance by the Purchaser of the transactions contemplated by this Agreement have
been duly authorized by all necessary limited liability company action on the part of the Purchaser. Each Golisano Investment
Document to which it is a party has been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with
the terms hereof, will constitute the valid and legally binding obligation of the Purchaser, enforceable against it in accordance
with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by
other equitable principles of general application or insofar as indemnification and contribution provisions may be limited by
applicable law.

 

(b)          No
Conflicts. The execution, delivery and performance by the Purchaser of the Golisano Investment Documents to which it is a
party and the consummation by the Purchaser of the transactions contemplated hereby and thereby will not (i) result in a
violation of the Articles of Organization or the Operating Agreement of the Purchaser, (ii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights
of termination, amendment, acceleration or cancellation of, any material agreement, indenture or instrument to which the Purchaser
is a party or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and
state securities laws) applicable to the Purchaser, except in the case of clauses (ii) and (iii) above, for such conflicts,
defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse
effect on the ability of the Purchaser to perform its obligations hereunder.

 

(c)          Investment
Intent. The Purchaser understands that the Securities are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and that it is acquiring the Securities as principal for its own
account and not with a view to, or for distributing or reselling such Securities or any part thereof in violation of the Securities
Act or any applicable state securities laws, provided, however, that by making the representations herein, the Purchaser
does not agree to hold any of the Securities for any minimum period of time and reserves the right, subject to the provisions
of this Agreement, at all times to sell or otherwise dispose of all or any part of such Securities pursuant to an effective registration
statement under the Securities Act or under an exemption from such registration and in compliance with applicable federal and
state securities laws. The Purchaser is acquiring the Securities hereunder in the ordinary course of its business. The Purchaser
does not presently have any agreement, plan or understanding, directly or indirectly, with any Person to distribute or effect
any distribution of any of the Securities (or any securities which are derivatives thereof) to or through any person or entity;
the Purchaser is not a registered broker-dealer under Section 15 of the Exchange Act or an entity engaged in a business that
would require it to be so registered as a broker-dealer.

 

(d)          Purchaser
Status. At the time the Purchaser was offered the Securities, it was, and at Execution Date, it is, an “accredited investor”
as defined in Rule 501(a) under the Securities Act.

 

    24 

     

    

 

(e)          General
Solicitation. The Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented
at any seminar or any other general advertisement.

 

(f)          Experience
of the Purchaser. The Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. The Purchaser is able to bear the economic risk
of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

 

(g)          Access
to Information. The Purchaser acknowledges that it has had the opportunity to review the Disclosure Materials and has been
afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, officers of
the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the
Securities; (ii) access to information about the Company and its respective financial condition, results of operations, business,
properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain
such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment. Neither such inquiries nor any other investigation conducted
by or on behalf of the Purchaser or its representatives or counsel shall modify, amend or affect the Purchaser’s right to
rely on the truth, accuracy and completeness of the Disclosure Materials and the Company’s representations and warranties
contained in the Golisano Investment Documents (as qualified by the Disclosure Materials).

 

(h)          Certain
Trading Activities. Other than with respect to the transactions contemplated herein, since the time that the Purchaser was
first contacted by the Company or any other Person regarding the transactions contemplated hereby, neither the Purchaser nor,
to the knowledge of the Purchaser, any Affiliate of the Purchaser which (i) had knowledge of the transactions contemplated
hereby, (ii) has or shares discretion relating to the Purchaser’s investments or trading or information concerning
the Purchaser’s investments, including in respect of the Securities and (iii) is subject to the Purchaser’s review
or input concerning such Affiliate’s investments or trading (collectively, “Trading Affiliates”)
has directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding with the Purchaser or Trading
Affiliate, effected or agreed to effect any transactions in the securities of the Company (including, without limitation, any
Short Sales involving the Company’s securities). Notwithstanding the foregoing, and except as otherwise provided in Section 4.12,
neither the Purchaser nor any of its Trading Affiliates makes any representation, warranty or covenant hereby that it will not
engage in Short Sales in the securities of the Company after the effectiveness of the Registration Statement.

 

(i)           Brokers
and Finders. No Person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest
or claim against or upon the Company or any Purchaser for any commission, fee or other compensation pursuant to any agreement,
arrangement or understanding entered into by or on behalf of the Purchaser.

 

    25 

     

    

 

(j)           Independent
Investment Decision. The Purchaser has independently evaluated the merits of its decision to purchase Securities pursuant
to the Golisano Investment Documents. The Purchaser understands that nothing in this Agreement or any other materials presented
by or on behalf of the Company to the Purchaser in connection with the purchase of the Securities constitutes legal, tax or investment
advice. The Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary
or appropriate in connection with its purchase of the Securities.

 

(k)          Reliance
on Exemptions. The Purchaser understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying in part
upon the truth and accuracy of, and the Purchaser’s compliance with, the representations, warranties, agreements, acknowledgements
and understandings of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility
of the Purchaser to acquire the Securities.

 

(l)           No
Governmental Review. The Purchaser understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment
in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(m)         Regulation M.
The Purchaser is aware that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of Common
Stock and other activities with respect to the Common Stock by the Purchaser.

 

(n)          Residency.
The Purchaser’s principal executive offices are in the State of New York.

 

(o)          Trading
Market. The Purchaser acknowledges that the Securities are quoted over-the-counter, and that no securities issued by the Company
are listed on a national securities exchange.

 

The Company and the
Purchaser acknowledge and agree that no party to this Agreement has made or makes any representations or warranties with respect
to the transactions contemplated hereby other than those specifically set forth in this Article III and the Golisano Investment
Documents.

 

    26 

     

    

 

Article
4

 

OTHER
AGREEMENTS OF THE PARTIES

 

4.1          Transfer
Restrictions.

 

(a)          Compliance
with Laws. Notwithstanding any other provision of the Golisano Investment Documents, the Purchaser covenants that the Shares,
may only be disposed of pursuant to an effective registration statement under, and in compliance with the requirements of, the
Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements
of the Securities Act, and in compliance with any applicable state and federal securities laws. In connection with any transfer
of the Shares other than (i) pursuant to an effective registration statement, (ii) to the Company, (iii) to an
Affiliate of the Purchaser, (iv) pursuant to Rule 144 (provided that the Purchaser provides the Company with
reasonable assurances (in the form of seller and broker representation letters if required) that the Securities may be sold pursuant
to such rule) or Rule 144A, (v) pursuant to Rule 144 without the requirement that the Company be in compliance with
the current public information requirements of Rule 144 and without other restriction following the applicable holding period
or (vi) in connection with a bona fide pledge, the Company may require the transferor thereof to provide to the Company an
opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion
shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred
Shares under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms
of this Agreement and the Registration Rights Agreement and shall have the rights of the Purchaser under this Agreement and the
Registration Rights Agreement.

 

(b)          Legends.
Certificates evidencing the Closing Shares and, upon issuance the Warrant Shares, shall bear any legend as required by the “Blue
Sky” laws of any state and a restrictive legend in substantially the following form until such time as they are not required
under Section 4.1(c) (and a stock transfer order may be placed against transfer of the certificates for the Securities):

 

THESE SECURITIES HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED
BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY.

 

In addition, if the
Purchaser is an Affiliate of the Company, certificates evidencing the Shares issued to the Purchaser shall bear a customary “affiliates”
legend.

 

    27 

     

    

 

(c)          Removal
of Legends. Subject to the Company’s right to request an opinion of counsel as set forth in Section 4.1(a), the legend
set forth in Section 4.1(b) above shall be removable and the Company shall issue or cause to be issued a certificate without
such legend or any other legend (except for any “affiliates” legend as set forth in Section 4.1(b)) to the holder
of the applicable Shares upon which it is stamped if (i) such Shares are registered for resale under the Securities Act (provided
that, if the Purchaser is selling pursuant to the effective registration statement registering the Shares for resale, the Purchaser
agrees to only sell such Shares during such time that such registration statement is effective and not withdrawn or suspended,
and only as permitted by such registration statement), (ii) such Shares are sold or transferred in compliance with Rule 144 (if
the transferor is not an Affiliate of the Company), including without limitation in compliance with the current public information
requirements of Rule 144 if applicable to the Company at the time of such sale or transfer, and the holder and its broker have
delivered customary documents reasonably requested by the Transfer Agent and/or Company Counsel in connection with such sale or
transfer, or (iii) such Shares are eligible for sale under Rule 144 without the requirement that the Company be in compliance
with the current public information requirements of Rule 144 and without other restriction and Company Counsel has provided written
confirmation of such eligibility to the Transfer Agent. Any fees (with respect to the Transfer Agent, Company Counsel or otherwise)
associated with the removal of such legend shall be borne by the Company. At such time as a legend is no longer required for certain
Shares, the Company will no later than three (3) Trading Days following the delivery by the Purchaser to the Company or the
Transfer Agent (with concurrent notice and delivery of copies to the Company) of a legended certificate representing such Shares
(endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the reissuance and/or
transfer, and together with such other customary documents as the Transfer Agent and/or Company Counsel shall reasonably request),
deliver or cause to be delivered to the transferee of the Purchaser or the Purchaser, as applicable, a certificate representing
such Shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give
instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4.1.

 

(d)          Irrevocable
Transfer Agent Instructions. The Company shall issue Irrevocable Transfer Agent Instructions to its Transfer Agent, and any
subsequent Transfer Agent. The Company represents and warrants that no instruction other than the Irrevocable Transfer Agent Instructions
or instructions consistent therewith or otherwise contemplated hereby or thereby or by the other Transaction Documents or such
other documents as the Transfer Agent may request in connection with any such instructions will be given by the Company to its
Transfer Agent in connection with this Agreement, and that the Shares shall otherwise be freely transferable on the books and
records of the Company as and to the extent provided in and subject to the terms of this Agreement, the other Golisano Investment
Documents and applicable law.

 

(e)          Acknowledgement.
The Purchaser hereunder acknowledges its primary responsibilities under the Securities Act and accordingly will not sell or otherwise
transfer the Shares or any interest therein without complying with the requirements of the Securities Act. Purchaser acknowledges
that the delivery of the Irrevocable Transfer Agent Instructions and any removal of any legends from certificates representing
the Shares as set forth in this Section 4.1 is predicated on the Company’s reliance upon the Purchaser’s acknowledgement
in this Section 4.1(e).

 

4.2          Acknowledgment
of Dilution. The Company acknowledges that the issuance of the Shares may result in dilution of the outstanding shares of
Common Stock. The Company further acknowledges that its obligations under the Golisano Investment Documents, including without
limitation its obligation to issue the Shares pursuant to the Golisano Investment Documents, are, subject to the terms and conditions
expressly set forth in this Agreement, with respect to the Closing Shares, and the Warrant, with respect to the Warrant Shares,
unconditional and absolute and not subject to any right of set-off, counterclaim, delay or reduction, regardless of the effect
of any such dilution or any claim the Company may have against the Purchaser and regardless of the dilutive effect that such issuance
may have on the ownership of the other stockholders of the Company.

 

    28 

     

    

 

4.3          Furnishing
of Information.

 

(a)          Until
such time that the Purchaser no longer owns Securities (the “Reporting Period”), the Company covenants
to maintain the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain
extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after
Execution Date pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange
Act. Without limiting any of the Company’s obligations under the Registration Rights Agreement, during the Reporting Period,
if the Company is not required to file reports pursuant to such laws, it will prepare and furnish to the Purchaser and make publicly
available in accordance with Rule 144(c) such information as is required for the Purchaser to sell the Shares under Rule 144.
Without limiting any of the Company’s obligations under the Registration Rights Agreement, the Company further covenants
that it will take such further action as any holder of the Shares may reasonably request, to the extent required from time to
time to enable such Person to sell the Shares without registration under the Securities Act, including without limitation, within
the requirements of the exemption provided by Rule 144.

 

(b)          At
any time commencing on the Closing Date and ending at such time that all of the Shares may be sold without the requirement for
the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, if the
Company shall fail for any reason to satisfy the current public information requirement under Rule 144(c) (a “Public
Information Failure”) then, in addition to the Purchaser’s other available remedies, the Company shall pay
to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its
ability to sell the Securities, an amount in cash equal to two percent (2%) of the aggregate Purchase Price paid for the Shares
held by the Purchaser on the day of a Public Information Failure and on every thirtieth (30th) day (pro-rated for periods totaling
less than thirty days) thereafter until the earlier of (i) the date such Public Information Failure is cured, and (ii) such time
that such public information is no longer required for the Purchaser to transfer the Shares pursuant to Rule 144. The payments
to which a Purchaser shall be entitled pursuant to this Section 4.3(b) are referred to herein as “Public Information
Failure Payments.” Public Information Failure Payments shall be paid on the earlier of (A) the last day of the calendar
month during which such Public Information Failure Payments are incurred and (B) the third (3rd) Business Day after the event
or failure giving rise to the Public Information Failure Payments is cured. In the event the Company fails to make Public Information
Failure Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month
(prorated for partial months) until paid in full. Nothing herein shall limit the Purchaser’s right to pursue actual damages
for the Public Information Failure, and the Purchaser shall have the right to pursue all remedies available to it at law or in
equity including, without limitation, a decree of specific performance and/or injunctive relief. 

 

    29 

     

    

 

4.4          Form D
and Blue Sky. The Company agrees to timely file a Form D with respect to the Securities as and if required under Regulation D
and to provide a copy thereof to the Purchaser, if the Purchaser so requests in writing, promptly after such filing. The Company
shall take such action as the Company shall reasonably determine is necessary in order to qualify the Securities for sale to the
Purchaser at the Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws of the states of
the United States (or to obtain an exemption from such qualification), which, subject to the accuracy of the Company’s and
the Purchaser’s representations and warranties set forth herein, shall consist of the submission of all filings and reports
relating to the offer and sale of the Securities pursuant to Rule 506 of Regulation D required under applicable securities or
“Blue Sky” laws of the states of the United States following the Closing Date, and shall provide evidence of any such
action so taken to the Purchaser, if Purchaser so requests, in writing.

 

4.5          No
Integration. The Company shall not, and shall use its commercially reasonable efforts to ensure that the Affiliates of the
Company shall not, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2 of the Securities Act) that will be integrated with the offer or sale of the Securities in a manner that would
require the registration under the Securities Act of the sale of the Securities to the Purchaser, or that will be integrated with
the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require
stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing
of such subsequent transaction.

 

4.6          Securities
Laws Disclosure; Publicity. Within the time required by the Exchange Act, the Company will file a Current Report on Form 8-K
with the Commission describing the terms of the Transaction Documents (and including as exhibits to such Current Report on Form
8-K the material Transaction Documents). From and after the filing of the Form 8-K, Purchaser shall not be in possession of any
material, non-public information received from the Company or any of its respective officers, directors, employees or agents,
that is not disclosed in the Form 8-K unless the Purchaser shall have executed a written agreement regarding the confidentiality
and use of such information. Purchaser covenants that until such time as the transactions contemplated by this Agreement are publicly
disclosed by the Company as described in this Section 4.6, to maintain the confidentiality of all disclosures made to it
in connection with such transactions (including the existence and terms of such transactions).

 

4.7          Non-Public
Information. Except with respect to the material terms and conditions of the Transactions, the Company shall not and shall
cause each of its officers, directors, employees and agents, not to, provide any Purchaser with any information the Company believes
is material, non-public information regarding the Company from and after the filing of the Press Release without the express written
consent of the Purchaser, unless prior thereto the Purchaser shall have executed a written agreement regarding the confidentiality
and use of such information.

 

    30 

     

    

 

4.8          Indemnification.

 

(a)          Indemnification
of the Purchaser. Subject to this Section 4.8, the Company will indemnify and hold the Purchaser and its managers, officers,
members, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title), each Person who controls the Purchaser (within the meaning of Section 15 of the Securities
Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees
(and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title
or any other title) of such controlling Person (each, a “Purchaser Party”) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys’ fees and costs of investigation that any the Purchaser Party may suffer
or incur, as a result of, relating to or arising out of (a) any breach of any of the representations, warranties, covenants or
agreements made by the Company in this Agreement or in the other Golisano Investment Documents or (b) any action instituted against
the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is
not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Golisano Investment Documents
(except to the extent such action is based upon a breach of such Purchaser Party’s representations, warranties or covenants
under this Agreement or in the other Golisano Investment Documents). The representations, warranties, covenants and obligations
of the Company, and the rights and remedies that may be exercised by a Purchaser Party, shall not be limited or otherwise affected
by or as a result of any information furnished to, or any investigation made by or knowledge of, any Purchaser Party or any representative
of any Purchaser Party.

 

(b)          Conduct
of Proceedings Involving Indemnification. Promptly after receipt by any Person (the “Indemnified Person”)
of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any Action in
respect of which indemnity may be sought pursuant to Section 4.8(a), such Indemnified Person shall promptly notify the Company
in writing and the Company shall have the right to assume the defense thereof, including the employment of counsel reasonably
satisfactory to such Indemnified Person and the assumption of the payment of all fees and expenses; provided, however,
that the failure of any Indemnified Person so to notify the Company shall not relieve the Company of its obligations hereunder
except to the extent that the Company is actually and materially prejudiced by such failure to notify. In any such Action, any
Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense
of such Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually agreed to the retention of such
counsel; (ii) the Company shall have failed promptly to assume the defense of such Action and to employ counsel reasonably
satisfactory to such Indemnified Person in such Action; or (iii) in the reasonable judgment of counsel to such Indemnified
Person representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests
between them, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate
counsel. The Company shall not be liable for any settlement of any Action effected without its written consent, which consent
shall not be unreasonably withheld, delayed or conditioned. Without the prior written consent of the Indemnified Person, which
consent shall not be unreasonably withheld, delayed or conditioned, the Company shall not effect any settlement of any pending
or threatened Action in respect of which any Indemnified Person is a party, unless such settlement includes an unconditional release
of such Indemnified Person from all liability arising out of such Action.

 

    31 

     

    

 

(c)          Other
Indemnification Terms. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof
during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained
herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any
liabilities the Company may be subject to pursuant to law.

 

4.9          Reservation
of Shares of Common Stock. As of the date hereof, the Company has reserved and the Company
shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common
Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise
of the Warrant.

 

4.10        Listing
of Securities. In the time and manner required by the Principal Trading Market, the Company shall prepare and file with such
Trading Market any additional shares listing application that may be required by such Trading Market covering all of the Shares
and shall use its commercially reasonable efforts to take all steps necessary to maintain, so long as any other shares of Common
Stock shall be so listed, such listing.

 

4.11        Use
of Proceeds. The Company shall use the net proceeds from the sale of the Securities hereunder solely for funding the purchase
price due from the Company under the Acquisition Agreement.

 

4.12        Dispositions
and Confidentiality After Execution Date. The Purchaser shall not, and shall cause its Trading Affiliates not to: (a) sell,
offer to sell, solicit offers to buy, dispose of, loan, pledge or grant any right with respect to (collectively, a “Disposition”)
the Shares; or (b) engage in any hedging or other transaction which is designed or could reasonably be expected to lead to
or result in a Disposition of the Shares by the Purchaser or a Trading Affiliate, except, in each case, for Dispositions pursuant
to an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, and in
compliance with any applicable state and federal securities laws. In addition, the Purchaser agrees that for so long as it owns
any Common Stock, it will not enter into any Short Sale of Shares executed at a time when the Purchaser has no equivalent offsetting
long position in the Common Stock. For purposes of determining whether the Purchaser has an equivalent offsetting long position
in the Common Stock, shares that the Purchaser is entitled to receive within sixty (60) days (whether pursuant to contract
or upon conversion or exercise of convertible securities) will be included as if held long by the Purchaser. The Purchaser covenants
that neither it nor any Person acting on its behalf or pursuant to any understanding with it will engage in any transactions in
the Company’s securities (including, without limitation, any Short Sales involving the Company’s securities) during
the period from Execution Date until the earlier of such time as (i) the transactions contemplated by this Agreement are
first publicly announced as described in Section 4.6 or (ii) this Agreement is terminated in full pursuant to Section 6.16.
The Purchaser understands and acknowledges that the Commission currently takes the position that covering a short position established
prior to effectiveness of a resale registration statement with shares included in such registration statement would be a violation
of Section 5 of the Securities Act, as set forth in Division of Corporation Financing Compliance and Disclosure Interpretation
239.10 regarding short selling.

 

    32 

     

    

 

4.13        Acquisition
and Great Harbor Equity Financing Transactions.

 

(a)          The
Company shall not permit any amendment or modification to be made to, or any waiver of any provision or remedy under, the Acquisition
Documents or the Great Harbor Equity Financing Documents without Purchaser’s prior written consent.

 

(b)          The
Company shall give the Purchaser prompt notice: (i) of any breach or default (or any event or circumstance that, with or without
notice, lapse of time or both, could reasonably be expected to give rise to any breach) by any party to the Acquisition Documents
or the Great Harbor Equity Financing Documents; (ii) of the receipt of any written notice or other written communication from
any Person with respect to (A) any breach, default, termination or repudiation by any party to the Acquisition Documents or the
Great Harbor Equity Financing Documents , or (B) any dispute or disagreement between or among any parties to the Acquisition Documents
or the Great Harbor Equity Financing Documents ; and (iii) if, for any reason, the Company believes in good faith that there is
a dispute or disagreement between or among any parties to the Acquisition Documents or the Great Harbor Equity Financing Documents
..

 

4.14        Participation
in Future Financing. 

 

(a)          Upon
any issuance by the Company of New Securities (other than the Excluded Securities) for cash consideration, Indebtedness or a combination
thereof (a “Future Equity Issuance” ), the Purchaser shall have the right to participate in the Future
Equity Issuance up to an amount equal to its Common Stock Proportional Ownership of the New Securities on the same terms, conditions
and price provided for in the Future Equity Issuance. This right of participation in any Future Equity Issuance shall be in addition
to the Purchaser’s right to purchase additional shares of Common Stock under the Warrant.

 

(b)          No
less than fifteen (15) Business Days prior to the expected consummation of a Future Equity Issuance, the Company shall deliver
to the Purchaser a written notice of its intention to effect a Future Equity Issuance (“Pre-Equity Issuance Notice”),
which Pre-Equity Issuance Notice shall ask the Purchaser if it wants to review the details of such equity issuance (such additional
notice, a “Future Equity Issuance Notice”). Upon the Purchaser’s request, and only upon a request
by the Purchaser, for a Future Equity Issuance Notice, the Company shall within two days after such request, deliver to the Purchaser
a Future Equity Issuance Notice. The Future Equity Issuance Notice shall describe in reasonable detail the proposed terms of the
Future Equity Issuance, the amount of proceeds intended to be raised thereunder, the intended use of proceeds and the Person or
Persons through or with whom such Future Equity Issuance is proposed to be effected and shall include as an attachment a term
sheet or similar document relating thereto setting forth all of the material terms of the Future Equity Issuance.

 

(c)          If
the Purchaser desires to participate in a Future Equity Issuance it must provide written notice to the Company by not later than
5:00 p.m. (New York City time) on the 10th Business Day after it has received the Future Equity Issuance Notice that
such Purchaser is willing to participate in the Future Equity Issuance, and stating the amount of the Purchaser’s participation.

 

    33 

     

    

 

(d)          If
the Company does not receive from the Purchaser a request for a Future Equity Issuance Notice as of the deadline set forth in
Section 4.14(b) above or if a request is made for the Future Equity Issuance Notice and the Company does not receive an election
to participate in the Future Equity Issuance as of the deadline set forth in Section 4.14(c) above, then the Purchaser shall be
deemed to have notified the Company that it does not elect to participate in the Future Equity Issuance pursuant to this Section
4.14.

 

(e)          If
by 5:00 p.m. (New York City time) on the 10th Business Day after the Purchaser has received a Future Equity Issuance
Notice, it does not receive a notification by the Purchaser of its willingness to participate in the Future Equity Issuance in
an amount that is for the Purchaser’s full Common Stock Proportional Ownership amount of the New Securities being issued
in the Future Equity Issuance, then the Company may effect the that portion of such Future Equity Issuance that could have been
purchased by the Purchaser (together with the remaining balance of the Future Equity Issuance) on the terms and with those Persons
set forth in the Future Equity Issuance Notice.

 

(f)          The
Company and the Purchaser agree that if the Purchaser elects to participate in a Future Equity Issuance, the transaction documents
related to the Future Equity Issuance shall not include any term or provision whereby the Purchaser shall be required to agree
to any restrictions on trading as to any of the securities purchased pursuant to this Section 4.14 or be required to consent to
any amendment to or termination of, or grant any waiver, release or the like under or in connection with, this Agreement or any
of the other Golisano Investment Documents, without the prior written consent of the Purchaser.

 

(g)          Notwithstanding
anything to the contrary in this Section 4.14 and unless otherwise agreed to by the Purchaser, the Company shall either confirm
in writing to the Purchaser that the transaction with respect to the Future Equity Issuance has been abandoned or shall publicly
disclose its intention to issue the securities in the Future Equity Issuance, in either case in such a manner such that the Purchaser
will not be in possession of any material, non-public information, by the twentieth (20th) Business Day following delivery of
the Future Equity Issuance Notice. If by such twentieth (20th) Business Day, no public disclosure regarding a transaction with
respect to the Future Equity Issuance has been made, and no notice regarding the abandonment of such transaction has been received
by the Purchaser, then such transaction shall be deemed to have been abandoned and the Purchaser shall not be deemed to be in
possession of any material, non-public information with respect to the Company or any of its Subsidiaries that relates to the
Future Equity Issuance.

 

Article
5

CONDITIONS PRECEDENT TO CLOSING

 

5.1          Conditions
Precedent to the Obligations of the Purchaser to Purchase Securities at the Closing. The obligation of the Purchaser to acquire
Securities at the Closing is subject to the fulfillment to the Purchaser’s satisfaction, on or prior to the Closing Date,
of each of the following conditions, any of which may be waived by the Purchaser:

 

    34 

     

    

 

(a)          Representations
and Warranties. The representations and warranties of the Company contained herein shall be true and correct in all material
respects (except for those representations and warranties which are qualified as to materiality, in which case such representations
and warranties shall be true and correct in all respects) as of the date when made and as of the Closing Date, as though made
on and as of such date, except for such representations and warranties that speak as of a different specified date.

 

(b)          Performance.
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Golisano Investment Documents to be performed, satisfied or complied with by it at or prior to the Closing.

 

(c)          No
Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any
of the transactions contemplated by the Transaction Documents.

 

(d)          Consents.
The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers necessary
for consummation of the purchase and sale of the Securities at the Closing (including all Required Approvals, except for those
set forth in clauses (i), (ii), (iii) and (v) of Section 3.1(e), which may be obtained after the Closing), all of which shall
be and remain so long as necessary in full force and effect.

 

(e)          No
Suspensions of Trading in Common Stock. The Common Stock shall not have been suspended, as of the Closing Date, by the
Commission.

 

(f)          Company
Deliverables. The Company shall have delivered the Company Deliverables in accordance with Section 2.2(a).

 

(g)          Tolworthy
Surrender of Shares of Common Stock. The Tolworthy Share Surrender Transaction shall have been consummated, and Thomas A.
Tolworthy shall have confirmed in writing to the Company and the Purchaser that he has no further right to purchase additional
shares of Common Stock pursuant to any existing contractual agreement except for (i) shares that he may be eligible to receive
pursuant to applicable employee stock incentive programs pursuant to his employment agreement with the Company, and (ii) any pre-emptive
right agreement approved by both the Board and the Purchaser.

 

(h)          Amendments
to Derivative Securities to Remove Anti-Dilution Adjustment. All Derivative Securities issued by the Company as of or prior
to the Execution Date (including those issued by the Company in June 2015) shall be amended, on terms and conditions satisfactory
to Purchaser in its sole discretion to remove any ratchet anti-dilution
or similar provisions that would result in a price or share adjustment and copies of all such amendments shall have been provided
to Purchaser and be satisfactory to Purchaser; provided, however this shall not apply to warrants originally represented by Warrant
No. W-2 issued to Penta Mezzanine SBIC Fund I, LP on February 6, 2015 for the purchase of 4,960,740 shares of Common Stock, Warrant
Nos. 2015-2 and 2015-3 issued to JL-BBNC Mezz Utah, LLC on January 22, 2015 for the purchase of 1,164,700 shares of Common Stock
respectively, or Warrant No. 2015-13 issued to JL Properties, Inc. on April 30, 2015 for the purchase of 465,880 shares of Common
Stock. Without limiting the foregoing, none of the Derivative Securities (other than the warrants originally represented by Warrant
Nos. W-2, 2015-2, 2015-3, and 2015-13) shall have any anti-dilution adjustment as a result of the Transaction.

 

    35 

     

    

 

(i)           Capstone
Agreement Amendment. The Capstone Agreement shall have been amended in form and substance acceptable to Purchaser in its sole
discretion and copy of the fully executed amendment shall have been provided to the Purchaser.

 

(j)           Consummation
of Great Harbor Equity Financing. The Great Harbor Equity Financing Transactions shall have been consummated pursuant to the
Great Harbor Equity Financing Documents without giving effect to any modifications, consents, amendments or waivers thereto unless
the Purchaser shall have provided its written consent thereto, and the Company shall have provided Purchaser with duplicate copies
of the executed Great Harbor Equity Financing Documents evidencing such consummation.

 

(k)          Consummation
of Acquisition. The Acquisition shall have been (or, substantially contemporaneously with the Closing hereunder, will be)
consummated pursuant to the Acquisition Agreement without giving effect to any modifications, consents, amendments or waivers
thereto unless the Purchaser shall have provided its written consent thereto, and the Company shall have provided Purchaser with
duplicate copies of the executed Acquisition Documents evidencing such consummation.

 

(l)           No
Company Material Adverse Effect. Since March 31, 2015, there shall not have been any effect, change, condition, fact, development,
occurrence or event that has had, or would reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect on the Company or its Subsidiaries.

 

(m)         No
Target Company Material Adverse Effect. Since March 31, 2015, there shall not have been any effect, change, condition, fact,
development, occurrence or event that has had, or would reasonably be expected to have, individually or in the aggregate, a Target
Company Material Adverse Effect.

 

(n)          Due
Diligence. Purchaser shall have completed and be satisfied in its sole discretion its financial, business and legal due diligence
with respect to the Company and its Subsidiaries and the Target Company.

 

(o)          Debt
Waiver and Amendments.

 

(i)          The
Company shall have received waivers of any and all defaults or events of default under its credit facilities with MidCap Funding
X Trust, Penta Mezzanine SBIC Fund I, L.P. and JL-Mezz Utah, LLC (f/k/a JL-BBNC Mezz Utah, LLC), and amendments to the credit
agreements, loan agreements or any other agreements of any kind with such lenders, and fully executed copies thereof and waivers
and amendments satisfactory in form and substance to the Purchaser shall be provided to the Purchaser.

 

(ii)         The
Purchaser shall have received a certificate in the form of Exhibit H hereto executed by the Company’s General Counsel.

 

    36 

     

    

 

(p)          Termination.
This Agreement shall not have been terminated in accordance with Section 6.16 herein.

 

5.2          Conditions
Precedent to the Obligations of the Company to sell Securities at the Closing. The Company’s obligation to sell and
issue the Securities to the Purchaser at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior
to the Closing Date of the following conditions, any of which may be waived by the Company:

 

(a)          Representations
and Warranties. The representations and warranties made by the Purchaser in Section 3.2 hereof shall be true and correct
in all material respects (except for those representations and warranties which are qualified as to materiality, in which case
such representations and warranties shall be true and correct in all respects) as of the date when made, and as of the Closing
Date as though made on and as of such date, except for representations and warranties that speak as of a different specified date.

 

(b)          Performance.
The Purchaser shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Golisano Investment Documents to be performed, satisfied or complied with by the Purchaser at or prior to the
Closing Date.

 

(c)          No
Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any
of the transactions contemplated by the Golisano Investment Documents.

 

(d)          Purchaser
Deliverables. The Purchaser shall have delivered its Purchaser Deliverables in accordance with Section 2.2(b).

 

(e)          Termination.
This Agreement shall not have been terminated in accordance with Section 6.16 herein.

 

Article
6

MISCELLANEOUS

 

6.1          Fees
and Expenses.

 

(a)          The
Company shall pay and be responsible for all of its own fees and expenses, including its advisers, counsel, accountants and other
experts, if any, and all other expenses incurred by Company in connection with the negotiation, preparation, execution, delivery
and performance of this Agreement.

 

(b)          Without
regard to whether the Closing occurs, the Company shall pay and be responsible for all of Purchaser’s reasonable fees and
expenses, including its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by Purchaser
in connection with the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay
all of such fees and expenses incurred by Purchaser prior to the Closing, at the time of Closing and thereafter within ten (10)
days following a request therefor by Purchaser which is accompanied by written invoice documenting
in reasonable detail such fees and expenses of Purchaser (but not requiring detail time entries by the Purchaser's counsel).
The Company shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in connection with the sale and issuance
of the Securities to the Purchaser. 

 

    37 

     

    

 

6.2          Entire
Agreement. The Golisano Investment Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter thereof and supersede all prior agreements, understandings, discussions and
representations, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules. At or after the Closing, and without further consideration, the Company and the Purchaser will execute
and deliver to the other such further documents as may be reasonably requested in order to give practical effect to the intention
of the parties under the Golisano Investment Documents.

 

6.3          Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of (a) the Trading Day following the date of mailing, if sent by U.S.
nationally recognized overnight courier service with next day delivery specified, or (b) upon actual receipt by the party
to whom such notice is required to be given. The address for such notices and communications shall be as follows:

 

	If to the Company:	Twinlab Consolidated Holdings, Inc.
	 	632 Broadway, Suite 201
	 	New York, New York 10012
	 	Attention: General Counsel
	 	 
	With a copy to (which shall not	Wilk Auslander LLP
	constitute notice to the Company):	1515 Broadway
	 	New York, New York, 10036
	 	Attention:  Joel I. Frank
	 	 
	If to the Purchaser:	Golisano Holdings LLC
		One Fishers Road
	 	Pittsford, New York 14534
	 	Attention:  B. Thomas Golisano, Member
	 	 
	With a copy to (which shall not	Woods Oviatt Gilman, LLP
	constitute notice to the Purchaser):	Two State Street
	 	Rochester, New York 14614
	 	Attention:  Gordon E. Forth

 

or such other address as may be designated
in writing hereafter, in the same manner, by such Person.

 

    38 

     

    

 

6.4          Amendments;
Waivers; No Additional Consideration. No provision of this Agreement may be waived or amended except in a written instrument
signed, in the case of an amendment, by the Company and the Purchaser or, in the case of a waiver, by the party against whom enforcement
of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement
shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision,
condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner
impair the exercise of any such right.

 

6.5          Construction.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party. This Agreement shall be construed
as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue
of the authorship of any provisions of this Agreement or any of the Golisano Investment Documents.

 

6.6          Successors
and Assigns. The provisions of this Agreement shall inure to the benefit of and be binding upon the parties and their successors
and permitted assigns. This Agreement, or any rights or obligations hereunder, may not be assigned by the Company without the
prior written consent of the Purchaser (other than by merger or consolidation or to an entity which acquires the Company, including
by way of acquiring all or substantially all of the Company’s assets). The Purchaser may assign its rights hereunder in
whole or in part to any Person to whom the Purchaser assigns or transfers any Securities in compliance with the Golisano Investment
Documents and applicable law, provided such transferee shall agree in writing to be bound, with respect to the transferred Securities,
by the terms and conditions of this Agreement that apply to the “Purchaser.”

 

6.7          No
Third-Party Beneficiaries. Except with respect to Section 4.8, which may be enforced by any Purchaser Party, this Agreement
is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit
of, nor may any provision hereof be enforced by, any other Person.

 

6.8          Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof; provided, however, that, the laws of the State of Delaware will govern (i) whether a Target Material
Adverse Effect has occurred, (ii) compliance with any representations regarding the Acquisition Documents and (iii) whether the
Acquisition has been consummated in accordance with the terms of the Acquisition Documents. Each party agrees that all Actions
concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Golisano
Investment Documents (whether brought against a party hereto or its respective Affiliates, employees or agents) shall be commenced
exclusively in the New York Courts. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York
Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or
discussed herein (including with respect to the enforcement of any of the Golisano Investment Documents), and hereby irrevocably
waives, and agrees not to assert in any Action, any claim that it is not personally subject to the jurisdiction of any such New
York Court, or that such Action has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably
waives personal service of process and consents to process being served in any such Action by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY
HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY
LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

    39 

     

    

 

6.9          Survival.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities. The agreements
and covenants contained herein shall survive the Closing for the applicable statute of limitations.

 

6.10        Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding
obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile
or “.pdf” signature page were an original thereof.

 

6.11        Severability.
If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor and achieves that same or substantially
the same effect or result, and upon so agreeing, shall incorporate such substitute provision in this Agreement.

 

6.12        Replacement
of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company and the Transfer
Agent of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of
that fact and an agreement to indemnify and hold harmless the Company and the Transfer Agent for any losses in connection therewith
or, if required by the Transfer Agent, a bond in such form and amount as is required by the Transfer Agent. The applicants for
a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance
of such replacement Securities. If a replacement certificate or instrument evidencing any Securities is requested due to a mutilation
thereof, the Company may require delivery of such mutilated certificate or instrument as a condition precedent to any issuance
of a replacement.

 

    40 

     

    

 

6.13        Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Purchaser
and the Company will be entitled to specific performance under the Golisano Investment Documents. The parties agree that monetary
damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing
sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in connection with
any action for a temporary restraining order) the defense that a remedy at law would be adequate.

 

6.14        Payment
Set Aside. To the extent that the Company makes a payment or payments to Purchaser pursuant to any Golisano Investment Document
or the Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement
or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered
from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other
Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of
action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be
revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

 

6.15        Adjustments
in Share Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares of Common
Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares
of Common Stock), combination or other similar recapitalization or event occurring after the Execution Date, each reference in
any Golisano Investment Document to a number of shares or a price per share shall be deemed to be amended to appropriately account
for such event.

 

6.16        Termination.

 

(a)          This
Agreement may be terminated and the sale and purchase of the Securities abandoned at any time after the Execution Date and prior
to the Closing by:

 

(i)          mutual
written consent of the Company and the Purchaser; or

 

(ii)         either
the Company or the Purchaser, upon written notice to the other, if the Acquisition Agreement is terminated at any time;

 

(iii)        either
the Company or the Purchaser, upon written notice to the other, if the Closing has not been consummated on or prior to 5:00 p.m.,
New York City time, on the earlier of (i) the Outside Date, or (ii) October 30, 2015, unless the Purchaser has provided written
consent to an extension in its sole discretion; provided, however, that the right to terminate this Agreement under this
Section 6.16 shall not be available to any Person whose failure to comply with its obligations under this Agreement has been the
cause of or resulted in the failure of the Closing to occur on or before such time.

 

    41 

     

    

 

6.17        Effect
of Termination. In the event of the termination of this Agreement as provided in Section 6.16, this Agreement shall be of
no further force or effect provided, however, that: (a) this Article 6 shall survive the termination of this Agreement and shall
remain in full force and effect, and (b) the termination of this Agreement shall not relieve any party from any liability for
any breach of this Agreement or fraud or impair the right of any party to compel specific performance by any other party of its
obligations under this Agreement or the other Golisano Investment Documents.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

[SIGNATURE PAGE FOLLOWS]

 

    42 

     

    

 

In
Witness Whereof, the parties hereto have caused this Securities
Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

	 	TWINLAB CONSOLIDATED HOLDINGS, INC.
	 	 	 
	 	By:	/s/ Thomas A. Tolworthy
	 	Name:  Thomas A. Tolworthy
	 	Title:  President and Chief Executive Officer
	 	 	 
	 	GOLISANO HOLDINGS LLC
	 	 	 
	 	By:	/s/ B. Thomas Golisano
	 	Name:  B. Thomas Golisano
	 	Title:    Member

 

     

     

    

 

EXHIBITS:

 

		A:	Form of Warrant

		B:	Form of Registration Rights Agreement

		C:	Form of Voting Agreement

		D	Irrevocable Transfer Agent Instructions

		E:	Form of Secretary’s Certificate

		F:	Form of Compliance Certificate

		G:	Form of Legal Opinion

		H:	Form of Section 5.1(o) Officer’s
                                         Certificate

 

     

     

    

 

EXHIBIT
A

Form of WARRANT

 

See attached.

 

     

     

    

 

EXHIBIT
b

Form of REGISTRATION RIGHTS Agreement 

 

See attached.

 

     

     

    

 

EXHIBIT
C

Form of VOTING Agreement 

 

See attached.

 

     

     

    

 

EXHIBIT
d

Form of Irrevocable Transfer Agent Instructions

 

[_________], 2015

[Transfer Agent]

____________________

____________________

____________________

Attn: [____________]

 

Ladies and Gentlemen:

 

Reference is made
to that certain Securities Purchase Agreement, dated as of _________, 2015 (the “Agreement”), by and
between Twinlab Consolidated Holdings, Inc., a Nevada corporation (the “Company”), and [__________________]
(including permitted transferees, the “Holders”), pursuant to which the Company is issuing to the Holders
shares (the “Shares”) of Common Stock of the Company, par value $0.001 per share (the “Common
Stock”).

 

This letter shall
serve as our irrevocable authorization and direction to you (provided that you are the transfer agent of the Company at such time
and the conditions set forth in this letter are satisfied), subject to any stop transfer instructions that we may issue to you
from time to time, if any, to (i) issue, promptly following the date hereof, certificates representing the Shares bearing
the legend set forth herein below, in the names of the Holders and the number of Shares as set forth in the attachments delivered
herewith, and to deliver such certificates within three (3) business days after the date hereof to the address for each such Holder
as set forth on such attachments delivered herewith, and (ii) issue certificates representing shares of Common Stock upon
transfer or resale of the Shares, which certificates shall or shall not bear the legend set forth herein below as described below.

 

You acknowledge and
agree that so long as you have received (a) written confirmation from the Company’s legal counsel that a registration
statement covering resales of the Shares has been declared effective by the Securities and Exchange Commission (the “Commission”)
under the Securities Act of 1933, as amended (the “Securities Act”), a copy of such registration statement
and any other documents reasonably requested by you from the applicable Holder (and provided that you have not received written
instruction from the Company or its legal counsel that such registration statement has been suspended or is no longer effective),
(b) written confirmation from the Company’s legal counsel that the Shares are eligible for sale in conformity with Rule
144 under the Securities Act (“Rule 144”) and customary documentation from a Holder and its broker with
respect to a sale pursuant to Rule 144, or (c) written confirmation from the Company’s legal counsel that the Shares are
eligible for sale without the requirement that the Company be in compliance with the current public information requirements of
Rule 144 and without other restriction in conformity with Rule 144, then, unless otherwise required by law, within three (3) business
days of your receipt of certificate of Common Stock and documentation required pursuant to clause (a) or (b) above, as applicable,
or a request from a Holder for the issuance of an unlegended certificate in the event that you have received the written confirmation
set forth in clause (c) above, you shall issue the certificates representing the Shares registered in the names of the purchaser
of such Shares or the Holder, as the case may be, and such certificates shall not bear any legend restricting transfer of the
Shares thereby and should not be subject to any stop-transfer restriction.

 

     

     

    

 

All certificates representing
the Shares issued pursuant to the instruction set forth in clause (i) of the second paragraph of this letter shall bear the following
legend (and, solely to the extent instructed to you by the Company or its legal counsel, a customary “affiliates”
legend), and, in the event that you have not received the documentation required pursuant to clause (a), (b) or (c) of the immediately
preceding paragraph, then the certificates representing any shares of Common Stock issued pursuant to the instruction set forth
in clause (ii) of the second paragraph of this letter shall bear the following legend:

 

THESE SECURITIES
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED
BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY.

 

Please be advised
that the Holders are relying upon this letter as an inducement to enter into the Agreement and, accordingly, each Holder is a
third party beneficiary to these instructions.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

[SIGNATURE PAGE FOLLOWS]

 

     

     

    

 

Please execute this
letter in the space indicated to acknowledge your agreement to act in accordance with these instructions.

 

	 	Very truly yours,
	 	 
	 	TWINLAB CONSOLIDATED HOLDINGS, INC.
	 	 	 
	 	By:	
	 	Name:  Thomas A. Tolworthy
	 	Title:  President and Chief Executive Officer

 

Acknowledged and Agreed:

 

TRANSFER AGENT:

 

	By:	 
	Name: 	 
	Title:  	 

 

	Date: 	 

 

     

     

    

 

EXHIBIT
e

Form of Secretary’s Certificate

 

Date: October ___, 2015

 

The undersigned hereby
certifies that he is the duly elected, qualified and acting Secretary of Twinlab Consolidated Holdings, Inc., a Nevada corporation
(the “Company”), and that as such he is authorized to execute and deliver this certificate in the name
and on behalf of the Company and in connection with the Securities Purchase Agreement, dated as of October ___, 2015, by and between
the Company and the Purchaser party thereto (the “Securities Purchase Agreement”), and further certifies
in his official capacity, in the name and on behalf of the Company, the items set forth below. Capitalized terms used but not
otherwise defined herein shall have the meaning set forth in the Securities Purchase Agreement.

 

1.          Attached
hereto as Exhibit A is a true, correct and complete copy of the resolutions duly adopted by the Board of Directors of the
Company at a meeting of the Board of Directors held on, or by unanimous written consent dated __________, 2015. Such resolutions
have not in any way been amended, modified, revoked or rescinded, have been in full force and effect since their adoption to and
including the date hereof and are now in full force and effect.

 

2.          Attached
hereto as Exhibit B is a true, correct and complete copy of the Articles of Incorporation of the Company, together with
any and all amendments thereto currently in effect, and no action has been taken to further amend, modify or repeal such Articles
of Incorporation, the same being in full force and effect in the attached form as of the date hereof.

 

3.          Attached
hereto as Exhibit C is a true, correct and complete copy of the Bylaws of the Company and any and all amendments thereto
currently in effect, and no action has been taken to further amend, modify or repeal such Bylaws, the same being in full force
and effect in the attached form as of the date hereof.

 

4.          Each
person listed below has been duly elected or appointed to the position(s) indicated opposite his name and is duly authorized to
sign the Securities Purchase Agreement and each of the Transaction Documents on behalf of the Company, and the signature appearing
opposite such person’s name below is such person’s genuine signature.

 

	Name	 	Position	 	Signature
	 	 	 	 	 
	Thomas A. Tolworthy	 	President and Chief Executive Officer	 	 
	 	 	 	 	 
	 	 	 	 	 

 

     

     

    

 

In
Witness Whereof, the undersigned has executed this Secretary’s Certificate as of the date first written above.

 

	 	
	 	Richard H. Neuwirth
	 	Secretary

 

I, Thomas A. Tolworthy,
President and Chief Executive Officer of the Company, hereby certify that Richard H. Neuwirth is the duly elected, qualified and
acting Secretary of the Company and that the signature set forth above is his true signature.

 

	 	
	 	Thomas A. Tolworthy
	 	President and Chief Executive Officer

 

     

     

    

 

EXHIBIT
f

COMPLIANCE CERTIFICATE 

 

See attached.

 

     

     

    

 

EXHIBIT
G

Form of legal opinion 

 

See attached.

 

     

     

    

 

EXHIBIT
H

Section
5.1(o) Officer’s Certificate

 

See attached.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}]]